var title_f4_52_4928="Action of prog antags";
var content_f4_52_4928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Action of PAs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PAs compete with agonist for binding to PR and promote the activation steps of dimerization and binding to specific PREs of target DNA. However PAs induce an altered conformation in PR that is transcriptionally inactive, resulting in a nonproductive interaction of receptor with DNA. This is caused by PR recruitment of corepressors (NCoR and SMRT) instead of coactivators.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Leonhardt, SA, Edwards, DP. Exp Biol Med 2002; 227:969. Copyright &copy; 2005 Society for Experimental Biology and Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4928=[""].join("\n");
var outline_f4_52_4928=null;
var title_f4_52_4929="U-S fetal corpus callosum cavum septum pellucidum cavum vergae";
var content_f4_52_4929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Corpus callosum, cavum septum pellucidum and cavum vergae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4929=[""].join("\n");
var outline_f4_52_4929=null;
var title_f4_52_4930="Magnetic resonance images pediatric appendicitis";
var content_f4_52_4930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Axial and coronal magnetic resonance images showing appendicitis in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axial (A) and coronal (B) images show an enlarged and inflamed appendix (arrows). These are noncontrast T-2 images obtained from a three Tesla magnet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George A Taylor, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4930=[""].join("\n");
var outline_f4_52_4930=null;
var title_f4_52_4931="Sodium fluoride F18: Drug information";
var content_f4_52_4931=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium fluoride F18: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/48/37634?source=see_link\">",
"    see \"Sodium fluoride F18: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15404829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15508818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     PET scan should be done within 1-2 hours of administration. Calculate volume to administer based on calibration time and dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: 300-450 MBq (8-12 mCi)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F15508817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     PET scan should be done within 1-2 hours of administration. Calculate volume to administer based on calibration time and dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Weight-based doses (2.1 MBq/kg [0.06 mCi/kg]) ranging from 19-148 MBq (0.5-4 mCi) were reported in clinical experience.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15508823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wear waterproof gloves and use protective shielding when handling and administering sodium fluoride F18. See manufacturer&rsquo;s prescribing information for complete administration procedure.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15404831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used in conjunction with positron emission tomography (PET) for imaging of bone to define areas of altered osteogenic activity",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15404826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15508799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adverse events have been reported at this time.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15404844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15404845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel (eg, wear waterproof gloves and use effective shielding). Use only under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cancer: Patients are exposed to some radiation during treatment; large cumulative amounts of radiation exposure may increase the risk of cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Absorbed radiation: Bone, bone marrow, and urinary bladder are target organs for high absorbed radiation doses. To minimize the radiation-absorbed dose to the bladder, encourage patients to drink &ge;500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Appropriate use:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Imaging: Patients should void immediately before imaging the radioactivity in the lumbar spine or bony pelvis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: May localize in areas of bone turnover, including developing long bones. Children are more sensitive to radiation; therefore, the lowest radiation-absorbed dose should be utilized to minimize risk to the patient and provide quality imaging (Gelfand, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15594464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15594462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15404832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15404833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproductive and developmental studies have not been conducted. Radiopharmaceuticals have the potential to cause fetal harm. Women should be evaluated for pregnancy prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15404834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15404838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reactions in the nursing infant, breast-feeding is not recommended. The manufacturer recommends interrupting breast-feeding for &ge;24 hours to minimize radioactivity exposure and risk to the infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15508822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To minimize the radiation-absorbed dose to the bladder, encourage patients to drink &ge;500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15508807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluoride F18 ion accumulates in the skeleton with increased deposition in the vertebrae and pelvis to define areas of abnormal osteogenic activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15508809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Blood, bone; only ~10% of dose remains in blood 1 hour after administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Biexponential: First phase: 0.4 hours; Second phase: 2.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&ge;20% within the first 2 hours after administration)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gelfand MJ, Parisi MT, Treves ST, et al, \"Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines,\"",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 2011, 52(2):318-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/52/4931/abstract-text/21233182/pubmed\" id=\"21233182\" target=\"_blank\">",
"        21233182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Segall G, Delbeke D, Stabin MG, et al, \"SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0,\"",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 2010, 51(11):1813-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/52/4931/abstract-text/21051652/pubmed\" id=\"21051652\" target=\"_blank\">",
"        21051652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87030 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4931=[""].join("\n");
var outline_f4_52_4931=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404829\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15508818\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15508817\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15508823\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404831\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404826\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15508799\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404844\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404845\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594464\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15594462\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404832\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404833\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404834\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15404838\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15508822\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15508807\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15508809\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87030|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/48/37634?source=related_link\">",
"      Sodium fluoride F18: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_52_4932="Genesis of schistocyte";
var content_f4_52_4932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Genesis of the schistocyte",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This scanning electron microphotograph shows a red blood cell (white arrow) about to be \"guillotined\" by a fibrin strand (yellow arrow), produced as a result of intravascular coagulation. This results in the formation of a fragmented red blood cell, termed a schistocyte or \"helmet cell.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Bull, BS, Kuhn, IN: The production of schistocytes by fibrin strands (a scanning electron microscope study). Blood 1970; 35:104. Copyright American Society of Hematology, used by permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4932=[""].join("\n");
var outline_f4_52_4932=null;
var title_f4_52_4933="Recluse spider B";
var content_f4_52_4933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Female recluse spider B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spider appears larger than actual size. Mature recluse spiders have a body length (not including legs) of 7 to 10 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard S Vetter, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4933=[""].join("\n");
var outline_f4_52_4933=null;
var title_f4_52_4934="Seborrheic keratosis superficial";
var content_f4_52_4934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large superficial seborrheic keratosis on the cheek of a 56-year-old woman.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permisison from: the Dermatology Online Atlas,",
"     <a href=\"file://www.dermis.net\" target=\"_blank\">",
"      www.dermis.net",
"     </a>",
"     . Copyright &copy; 2011. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4934=[""].join("\n");
var outline_f4_52_4934=null;
var title_f4_52_4935="Post-traumatic seizures and epilepsy";
var content_f4_52_4935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-traumatic seizures and epilepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4935/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4935/contributors\">",
"     Randolph W Evans, MD, FAAN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4935/contributors\">",
"     Steven C Schachter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4935/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4935/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4935/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4935/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/52/4935/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are a long recognized complication of traumatic brain injury (TBI). Seizures that occur early versus late after TBI have different implications for prognosis and management. Early seizures are felt to be acute symptomatic events with a low likelihood of recurrence, whereas late seizures represent epilepsy.",
"   </p>",
"   <p>",
"    While only 4 percent of all epilepsy cases are attributed to trauma, 13 percent of those cases that are of known cause are post-traumatic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/1\">",
"     1",
"    </a>",
"    ]. TBI is also the most important cause of symptomatic epilepsy in persons aged 15 to 24 years. Post-traumatic epilepsy contributes significantly to the functional disability in a TBI survivor.",
"   </p>",
"   <p>",
"    This topic will discuss epidemiologic, clinical, management and prognostic issues that are specific to post-traumatic seizures. More general issues related to seizures and epilepsy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early post-traumatic seizures are defined by their occurrence within one week of head trauma. These are acute symptomatic events and are not felt to represent epilepsy.",
"   </p>",
"   <p>",
"    A distinct category of immediate seizures, those occurring upon or within seconds of impact, is controversial. Some feel that these are \"convulsive concussions\" and not epileptic events [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/2\">",
"     2",
"    </a>",
"    ]; others include them in the category of early seizures because of their similar associated risk for post-traumatic epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, the incidence of early post-traumatic seizures is about 6 to 10 percent but may be as high as 30 percent in some groups, such as those with depressed skull fracture and intracerebral hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Early seizure rates are also higher in patients with more severe head injuries, subdural hematomas, and penetrating head injury, but they do occur in patients with mild traumatic brain injury (TBI) and normal head CT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Younger age is also a risk factor for early seizures. In one series of patients, 31 percent of children younger than seven years had early seizures compared with 20 percent of children aged 8 to 16 years and 8.4 percent of children over 16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-half of early post-traumatic seizures occur during the first 24 hours, and one-quarter occur within the first hour [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most seizures (72 to 84 percent) presenting within the first day are generalized tonic clonic type [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. The later a seizure begins in relationship to the head injury, the more likely it will be focal in onset; after the first day, more than half are either simple partial (pure motor) seizures or focal with secondary generalization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. Complex partial seizures are rare in this setting.",
"   </p>",
"   <p>",
"    About 10 percent of patients with acute head injury develop status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. This is more common in children and usually accompanies other underlying complications such as ischemia or metabolic imbalance. Focal motor status epilepticus is most common with subdural hematoma or depressed skull fracture and may be refractory to treatment. Mortality with generalized status epilepticus is high even when associated with mild TBI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate and severe TBI routinely have a head CT as part of their injury evaluation. Head CT is also required in patients with early post-traumatic seizures after a mild TBI; early seizures are associated with a higher incidence of intracranial bleeding, which may in turn increase the risk of short and long-term complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    .) While brain MRI is more sensitive for post-traumatic intracranial abnormalities, the implications of this added information for prognosis and management are less clear.",
"   </p>",
"   <p>",
"    EEG has limited utility in this setting. EEG abnormalities do not predict the risk or type of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/3\">",
"     3",
"    </a>",
"    ]. EEG patterns are often nonspecifically altered during the acute phase of head injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early post-traumatic seizures may not recur, patients with early seizures are often treated with antiepileptic drugs (AEDs) because of the risk of status epilepticus or aggravation of a systemic injury. In addition, recurrent seizures may increase cerebral blood flow and could theoretically increase intracranial pressure.",
"   </p>",
"   <p>",
"    In patients who have not had but appear to be at risk for early seizures, AED treatment reduces the incidence of early seizures and may be used because of similar concerns for secondary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above.) Pooled analysis of two randomized, controlled clinical trials using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    estimated the relative risk to be 0.37 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/12\">",
"     12",
"    </a>",
"    ]. In unselected patients, the seizure risk is low and not substantially reduced by treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no ideal AED for the management of early seizures. In practice,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    is often used because it does not cause significant sedation and is conveniently loaded intravenously. The optimal duration of therapy is not clear and depends in part upon the severity of injury. AEDs are generally continued throughout the hospital stay and are gradually withdrawn within the first few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/12,15\">",
"     12,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of AEDs after head injury does not reduce the risk of late seizures or post-traumatic epilepsy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early seizures are at higher risk for the development of post-traumatic epilepsy. Between 17 to 33 percent of patients with early seizures will develop epilepsy compared with a 2 percent overall incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some investigators believe that immediate seizures or \"concussive convulsions\" are more benign in terms of their risk for long-term seizures. In one study of 22 Australian rugby players with this phenomenon, none developed epilepsy over a mean follow-up of 3.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/2\">",
"     2",
"    </a>",
"    ]. Others have found a more similar prognosis for immediate seizures and all early seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that the association between early and late seizures reflects the shared risk factors for early and late seizures or that early seizures represent an independent risk factor for epilepsy. Multivariate analysis has given somewhat conflicting results. One population-based cohort study of 4541 adults and children with head injury followed for &gt;20 years did not find early seizures to be an independent risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/18\">",
"     18",
"    </a>",
"    ]. In a pooled analysis of a selected group of 783 high-risk trauma patients followed for two years as part of a clinical trial, early seizures remained in the multivariate analysis as an independent risk factor for epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     POST-TRAUMATIC EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures occurring more than one week after head injury reflect more permanent structural and physiologic changes within the brain and usually represent the onset of post-traumatic epilepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Epidemiology and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 10-year incidence of epilepsy after traumatic brain injury (TBI) is estimated at about 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/19\">",
"     19",
"    </a>",
"    ]. The severity of TBI strongly correlates with risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/18,20-23\">",
"     18,20-23",
"    </a>",
"    ]. In one population-based cohort, the cumulative five-year probability of seizures was 0.5 percent in patients with mild injury (those with loss of consciousness or amnesia &lt;30 minutes); 1.2 percent for those with moderate injuries (loss of consciousness for 30 minutes to 24 hours or skull fracture); and 10.0 percent in those with severe injuries (loss of consciousness or amnesia for more than 24 hours or subdural hematoma or cerebral contusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/18\">",
"     18",
"    </a>",
"    ]. Another study of 647 hospitalized patients categorized TBI severity more traditionally with the Glasgow Coma Scale (GCS) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/21\">",
"     21",
"    </a>",
"    ]. The two-year incidence of epilepsy was 8.0 percent for GCS 13 to 15 and 16.8 percent for GCS 3 to 8.",
"   </p>",
"   <p>",
"    Other subsets of patients at much higher risk have been identified and include those with early seizures, intracranial hemorrhage or cerebral contusion, depressed skull fracture, and penetrating head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/5,6,8,23\">",
"     5,6,8,23",
"    </a>",
"    ]. TBI associated with intracranial lesions on CT was associated with an 18 percent risk of late seizures in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/10\">",
"     10",
"    </a>",
"    ]. In penetrating missile combat injuries, the incidence is more than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. The requirement for neurosurgical procedure (hemorrhage evacuation, ventriculostomy) increased the risk, and multiple surgeries increased the risk over single surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to early seizures, older age, &gt;65 years, is a risk factor for post-traumatic epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/18\">",
"     18",
"    </a>",
"    ]. Post-traumatic epilepsy is less common in the pediatric population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. In one large, population-based study, the risk of post-traumatic epilepsy was slightly higher in women than men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic factors may influence the risk of developing seizures after epilepsy. Most studies have not found an increased risk of epilepsy among family members of patients with post-traumatic epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, one large, population-based cohort found that a family history of epilepsy increased the risk of post-traumatic epilepsy, with a relative risk estimate roughly equivalent to what would have been predicted from an additive risk model [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-traumatic seizures may be associated with the typical pathological changes that are seen in brain injuries including reactive gliosis, axon retraction balls, Wallerian degeneration, microglial scar formation, and cystic white matter lesions. There is also evidence suggesting that post-traumatic seizures may be a result of alterations of intrinsic membrane properties of pyramidal neurons together with enhanced N-methyl-D-aspartate synaptic conductances [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selective damage to the hilar region of the hippocampus is produced in animal models after fluid-percussion traumatic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/30\">",
"     30",
"    </a>",
"    ]. While this pattern of injury appears more restricted than the hippocampal sclerosis associated with temporal lobe epilepsy, some speculate that this mechanism may contribute to the development of post-traumatic epilepsy in some cases. In one pathologic case series, a similar pattern of hippocampal injury was found in all of the 21 patients undergoing epilepsy surgery for post-traumatic epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a contusion or cortical laceration is present, the breakdown of hemoglobin releases iron. Based on animal and cell culture studies, iron may increase intracellular calcium oscillation. It may also increase free radical formation through activation of the arachidonic acid cascade thereby producing increased intracellular calcium and resulting in excitotoxic damage, neuronal death, and glial scarring, which lead to epileptiform activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/32\">",
"     32",
"    </a>",
"    ]. These findings suggest a possible role for neuroprotective treatment in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI studies have the potential to add to our understanding of epileptogenesis after head injury. One study of 17 patients with post-traumatic epilepsy found that the presence of gadolinium enhancement was more common than in individuals with head trauma without epilepsy (77 versus 33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/33\">",
"     33",
"    </a>",
"    ]. Depending on the timing of the MRI, however, this finding may represent the effect rather than the cause of seizures. Using a specialized technique, diffusion tensor imaging, investigators have demonstrated that MRI characteristics associated with glial proliferation are more pronounced in head-injured patients with, rather than without, epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/34\">",
"     34",
"    </a>",
"    ]. In another study, in 135 patients with serial MRI examinations after TBI, hemosiderin deposits in the parenchyma associated with either incomplete or delayed surrounding gliosis were associated with the development of epilepsy compared with early hemosiderin completely surrounded by gliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 40 percent of individuals with post-traumatic epilepsy have onset within six months; 50 percent within one year; and about 80 percent within two years of head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/10,19\">",
"     10,19",
"    </a>",
"    ]. Post-traumatic epilepsy may begin more than 15 years later [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/9,18,20,23\">",
"     9,18,20,23",
"    </a>",
"    ]. The more severe the head injury, the longer the patient is at risk for late seizures; patients with mild TBI remain at risk for about five years, moderate TBI for 10 years, and severe TBI for 20 years or more [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary site of injury contributes to the symptomatic manifestation of epilepsy. Epilepsy appears earliest after lesions in the motor area followed by temporal lobe lesions and those in the frontal or occipital lobes. These seizures are usually secondarily generalized with or without apparent focal onset in 60 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/21,36\">",
"     21,36",
"    </a>",
"    ]. Simple and complex partial seizures each account for 10 to 20 percent. Primary generalized epilepsy has not been documented after head injury.",
"   </p>",
"   <p>",
"    Not all post-traumatic seizures are unprovoked. In one population-based cohort, there was a higher than expected incidence of alcohol withdrawal seizures, presumably a result of the relationship between alcohol ingestion and the risk of TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis and diagnostic approach to a patient with first late seizure is similar to the evaluation of any patient with a first seizure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    .) If there is a history of TBI within the past two years, particularly one associated with risk factors for epilepsy, then the diagnostic evaluation for underlying etiology may be curtailed. As an example, if a patient has a seizure with partial onset that corresponds to the site of brain injury, and has no fever or unexplained abnormalities on examination, then it may be reasonable to limit the evaluation to a neuroimaging study (CT or MRI) and basic laboratories (chemistries and toxicology screen). If the trauma history is more remote, or the injury mild, then an association between the seizure and trauma may be less clear, and a thorough evaluation should be completed.",
"   </p>",
"   <p>",
"    Brain MRI may be useful in ruling out other causes of epilepsy, but like EEG, it has no specific value in predicting either the development or remission of post-traumatic epilepsy. In patients whose seizures seem intractable to treatment or atypical of epilepsy, evaluation with video EEG can be helpful to rule out nonepileptic pseudoseizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .) In one center, 24 percent of patients with confirmed nonepileptic seizures had a history of head trauma and a diagnosis of presumed post-traumatic epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Management and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of seizures without treatment is likely, as high as 86 percent in the first two years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/36\">",
"     36",
"    </a>",
"    ]. As a result, long-term anticonvulsant treatment is recommended for patients after an initial late seizure. An antiepileptic drug active in partial epilepsy should be selected according to the considerations of age and comorbidity that apply to other individuals with new-onset epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remission rate for post-traumatic epilepsy is about 25 to 40 percent with initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/6\">",
"     6",
"    </a>",
"    ]. The event rate in the first year is predictive of the future course; patients having frequent seizures in the first year are less likely to have seizure remission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/24\">",
"     24",
"    </a>",
"    ]. Some will be refractory to treatment; over 13 percent of patients in the treatment groups of prophylactic antiepileptic drug (AED) trials had seizures despite aggressive treatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/6,38\">",
"     6,38",
"    </a>",
"    ]. Surgical therapy may be an option for some of these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"     \"Surgical therapy of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high incidence of post-traumatic epilepsy in some identified subgroups of head-injured patients and the potential for significant functional disability related to refractory epilepsy, many investigators have examined the potential of different preventative interventions. Animal models have shown encouraging results using AEDs as well as neuroprotective agents in preventing the development of post-traumatic epilepsy.",
"   </p>",
"   <p>",
"    Pooled analysis of six clinical trials of AEDs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) in 1405 patients with acute TBI found that AED therapy reduced early seizures but not late seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/13,38\">",
"     13,38",
"    </a>",
"    ]. Limitations in study design and execution of these trials, including delayed treatment, low power, primary use of older drugs with anticonvulsant rather than antiepileptic properties, and suboptimal dosing, may have contributed to the lack of demonstrated benefit in the prevention of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the failure to reduce the incidence of post-traumatic epilepsy is similar to the results of efforts to limit epileptogenesis in other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4935/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the absence of proven benefit for prophylactic AED therapy for the prevention of post-traumatic epilepsy and the known risk of the adverse effects of these medications, they are not recommended for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early and late seizures following traumatic brain injury (TBI) are distinct entities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early seizures occurring within one week are acute symptomatic events and are more common with intracranial hematoma, depressed skull fracture, severe injury, and in young children. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short-term use of antiepileptic drugs (AEDs) is recommended for the prevention of early seizures in patients who are at high risk and in whom seizures present a threat because of elevated intracranial pressure, systemic injury, or other reason (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seizures that occur after one week of TBI are likely to represent epilepsy. Except for age, late seizures share similar risk factors with early seizures. Post-traumatic epilepsy is more common in the elderly and relatively unusual in children. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A neuroimaging study (CT or MRI) is indicated for all patients with a new seizure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the high rate of recurrence, long-term treatment with AEDs is recommended after a first late post-traumatic seizure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Management and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have NOT had a late post-traumatic seizure, we suggest",
"      <strong>",
"       NOT",
"      </strong>",
"      using AEDs to prevent late seizures or post-traumatic epilepsy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). There is a lack of demonstrated efficacy in this setting and many potential adverse events with these medications. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Annegers, JF. The epidemiology of epilepsy, In: The treatment of epilepsy: Principles and practice, 3rd ed, Wyllie, E (Ed), Lippincott Williams, Philadelphia 2001. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/2\">",
"      McCrory PR, Bladin PF, Berkovic SF. Retrospective study of concussive convulsions in elite Australian rules and rugby league footballers: phenomenology, aetiology, and outcome. BMJ 1997; 314:171.",
"     </a>",
"    </li>",
"    <li>",
"     Barry E. Posttraumatic epilepsy, In: The treatment of epilepsy: Principles and practice, 3rd ed, Wyllie E (Ed), Lippincott Williams, Philadelphia 2001. p.609.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/4\">",
"      Emanuelson I, Uvebrant P. Occurrence of epilepsy during the first 10 years after traumatic brain injury acquired in childhood up to the age of 18 years in the south western Swedish population-based series. Brain Inj 2009; 23:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/5\">",
"      Temkin NR. Risk factors for posttraumatic seizures in adults. Epilepsia 2003; 44 Suppl 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/6\">",
"      Frey LC. Epidemiology of posttraumatic epilepsy: a critical review. Epilepsia 2003; 44 Suppl 10:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/7\">",
"      Lee ST, Lui TN. Early seizures after mild closed head injury. J Neurosurg 1992; 76:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/8\">",
"      Asikainen I, Kaste M, Sarna S. Early and late posttraumatic seizures in traumatic brain injury rehabilitation patients: brain injury factors causing late seizures and influence of seizures on long-term outcome. Epilepsia 1999; 40:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/9\">",
"      Pagni CA. Posttraumatic epilepsy. Incidence and prophylaxis. Acta Neurochir Suppl (Wien) 1990; 50:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/10\">",
"      Pagni CA, Zenga F. Posttraumatic epilepsy with special emphasis on prophylaxis and prevention. Acta Neurochir Suppl 2005; 93:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/11\">",
"      Neidlinger NA, Pal JD, Victorino GP. Head computed tomography scans in trauma patients with seizure disorder: justifying routine use. Arch Surg 2005; 140:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/12\">",
"      Chang BS, Lowenstein DH, Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 60:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/13\">",
"      Schierhout G, Roberts I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury. Cochrane Database Syst Rev 2001; :CD000173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/14\">",
"      Young KD, Okada PJ, Sokolove PE, et al. A randomized, double-blinded, placebo-controlled trial of phenytoin for the prevention of early posttraumatic seizures in children with moderate to severe blunt head injury. Ann Emerg Med 2004; 43:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/15\">",
"      Perron AD, Brady WJ, Huff JS. Concussive convulsions: emergency department assessment and management of a frequently misunderstood entity. Acad Emerg Med 2001; 8:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/16\">",
"      Barry, E, Bergey, GK, Krumholz, A, Eisenberg, H. Post-traumatic seizure types vary with the interval following head injury. Epilepsia 1997; 38 (Suppl 8):49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/17\">",
"      Kollevold T. Immediate and early cerebral seizures after head injuries. Part III. J Oslo City Hosp 1978; 28:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/18\">",
"      Annegers JF, Hauser WA, Coan SP, Rocca WA. A population-based study of seizures after traumatic brain injuries. N Engl J Med 1998; 338:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/19\">",
"      Annegers JF, Grabow JD, Groover RV, et al. Seizures after head trauma: a population study. Neurology 1980; 30:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/20\">",
"      Christensen J, Pedersen MG, Pedersen CB, et al. Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study. Lancet 2009; 373:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/21\">",
"      Englander J, Bushnik T, Duong TT, et al. Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation. Arch Phys Med Rehabil 2003; 84:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/22\">",
"      Ferguson PL, Smith GM, Wannamaker BB, et al. A population-based study of risk of epilepsy after hospitalization for traumatic brain injury. Epilepsia 2010; 51:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/23\">",
"      Raymont V, Salazar AM, Lipsky R, et al. Correlates of posttraumatic epilepsy 35 years following combat brain injury. Neurology 2010; 75:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/24\">",
"      Salazar AM, Jabbari B, Vance SC, et al. Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study. Neurology 1985; 35:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/25\">",
"      Schaumann BA, Annegers JF, Johnson SB, et al. Family history of seizures in posttraumatic and alcohol-associated seizure disorders. Epilepsia 1994; 35:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/26\">",
"      Ottman R, Lee JH, Risch N, et al. Clinical indicators of genetic susceptibility to epilepsy. Epilepsia 1996; 37:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/27\">",
"      Bush PC, Prince DA, Miller KD. Increased pyramidal excitability and NMDA conductance can explain posttraumatic epileptogenesis without disinhibition: a model. J Neurophysiol 1999; 82:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/28\">",
"      Goforth PB, Ellis EF, Satin LS. Mechanical injury modulates AMPA receptor kinetics via an NMDA receptor-dependent pathway. J Neurotrauma 2004; 21:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/29\">",
"      Kao CQ, Goforth PB, Ellis EF, Satin LS. Potentiation of GABA(A) currents after mechanical injury of cortical neurons. J Neurotrauma 2004; 21:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/30\">",
"      Golarai G, Greenwood AC, Feeney DM, Connor JA. Physiological and structural evidence for hippocampal involvement in persistent seizure susceptibility after traumatic brain injury. J Neurosci 2001; 21:8523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/31\">",
"      Swartz BE, Houser CR, Tomiyasu U, et al. Hippocampal cell loss in posttraumatic human epilepsy. Epilepsia 2006; 47:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/32\">",
"      Willmore LJ. Post-traumatic epilepsy: cellular mechanisms and implications for treatment. Epilepsia 1990; 31 Suppl 3:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/33\">",
"      Tomkins O, Shelef I, Kaizerman I, et al. Blood-brain barrier disruption in post-traumatic epilepsy. J Neurol Neurosurg Psychiatry 2008; 79:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/34\">",
"      Gupta RK, Saksena S, Agarwal A, et al. Diffusion tensor imaging in late posttraumatic epilepsy. Epilepsia 2005; 46:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/35\">",
"      Messori A, Polonara G, Carle F, et al. Predicting posttraumatic epilepsy with MRI: prospective longitudinal morphologic study in adults. Epilepsia 2005; 46:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/36\">",
"      Haltiner AM, Temkin NR, Dikmen SS. Risk of seizure recurrence after the first late posttraumatic seizure. Arch Phys Med Rehabil 1997; 78:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/37\">",
"      Barry E, Krumholz A, Bergey GK, et al. Nonepileptic posttraumatic seizures. Epilepsia 1998; 39:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/38\">",
"      Schierhout G, Roberts I. Prophylactic antiepileptic agents after head injury: a systematic review. J Neurol Neurosurg Psychiatry 1998; 64:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/39\">",
"      D'Ambrosio R, Perucca E. Epilepsy after head injury. Curr Opin Neurol 2004; 17:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4935/abstract/40\">",
"      Beghi E. Overview of studies to prevent posttraumatic epilepsy. Epilepsia 2003; 44 Suppl 10:21.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2213 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4935=[""].join("\n");
var outline_f4_52_4935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      POST-TRAUMATIC EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=related_link\">",
"      Surgical therapy of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15368?source=related_link\">",
"      Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_52_4936="Radical vulvectomy";
var content_f4_52_4936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radical vulvectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4936/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4936/contributors\">",
"     C William Helm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4936/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4936/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/52/4936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the standard operation for the treatment of even a small invasive carcinoma of the vulva was radical vulvectomy with removal of the primary tumor, including a wide area of skin extending onto the medial thigh, groins, and lower abdomen, together with an en bloc resection of the inguinal and often the pelvic lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/1\">",
"     1",
"    </a>",
"    ]. This operation had a high morbidity rate with approximately 50 percent of the wounds experiencing breakdown.",
"   </p>",
"   <p>",
"    Surgical procedures for the treatment of carcinoma of the vulva have become more conservative and individualized to each patient. The fundamental basis of surgery for the primary tumor is now complete excision with a minimum 2 cm margin and dissection down to the deep fascia and to the periosteum of the pubic symphysis. Although adenocarcinoma of the vulva is treated in much the same fashion as squamous cell carcinoma, involvement of Bartholin gland is still thought to require total radical vulvectomy. The management of malignant melanoma remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=see_link\">",
"     \"Disorders of Bartholin gland\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exact procedure used depends upon the site, size, and histologic features of the tumor (",
"    <a class=\"graphic graphic_picture graphicRef67807 \" href=\"UTD.htm?30/4/30784\">",
"     picture 1",
"    </a>",
"    ). The clitoris may be preserved if the tumor is situated posteriorly on the vulva or lies 2 cm or more from the clitoris or closer in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a groin node dissection is planned it is usually performed first, unless the patient's medical condition is uncertain, in such patients it is best to excise the vulva tumor first in case the anesthetic has to be abandoned.",
"   </p>",
"   <p>",
"    The extensive nature of some of the procedures, the unavoidable distortion of the appearance of the perineal area, and stoma formation can lead to major psychosexual problems for the patient. Preoperative counseling and postoperative support are vital parts of patient management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RADICAL VULVECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical vulvectomy implies removal of the entire vulva down to the level of the deep fascia of the thigh, the periosteum of the pubis, and the inferior fascia of the urogenital diaphragm. Because it is normally performed for malignant disease, the exact margins are defined by the extent of the tumor, but enough adjacent tissue should be removed to ensure a minimum 2 cm margin around a carcinoma. Radical vulvectomy is often performed in conjunction with either a unilateral or bilateral groin node dissection. The types of incisions used are individualized depending primarily on the site and size of the tumor (",
"    <a class=\"graphic graphic_figure graphicRef75367 \" href=\"UTD.htm?23/57/24465\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Modified radical vulvectomy including hemi-vulvectomy, can be performed for some lesions, either taking anterior or posterior portions, or the left or right side of the vulva, as appropriate. The important oncologic principle remains the same: adequate excision margins both on all sides and deep to the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women undergoing radical vulvar surgery require careful explanation and counseling about the effects of the procedure. Good bowel preparation is also a must before surgery. In view of the extensive dissection that may be necessary close to the anus, it is a good idea to document any signs of anal sphincter weakness before surgery. Symptoms of urinary incontinence should also be carefully assessed. Urinary incontinence may be an issue post-operatively, particularly with anterior radical vulvectomies, and may require surgical repair, medical management, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Operative procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;General, epidural, or spinal anesthesia is administered. The patient is placed in Allen stirrups with the hips abducted 45 degrees and flexed 45 degrees. It is helpful to position the patient so that the perineum protrudes over the bottom of the operating table. A pad or cushion is placed under the sacrum and the Bovie pad is kept off the thigh in case skin flaps need to be raised.",
"   </p>",
"   <p>",
"    The skin is prepared to include all areas that may be required for skin flaps. The patient is examined carefully to identify the limits of spread and then a pen is used to mark where the skin should be incised, both externally and within the vagina. A urethral catheter is inserted into the bladder. If frozen sections are required to ensure that the intended resection margins are clear of tumor, they should be taken at this time. They can be cut as small ellipses in the line of the incision. Only biopsies should be sent for frozen section, not the vulvectomy specimen.",
"   </p>",
"   <p>",
"    For a total radical vulvectomy the skin incision is begun posteriorly and extended laterally on both sides, similar to the procedure for a simple vulvectomy, but the excision margins are wider and the dissection is taken all the way through the subcutaneous fat to the deep fascia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14535?source=see_link\">",
"     \"Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tissues can be separated relatively easily from the deep fascia and pubic ramus with scalpel or scissors until the intended vaginal resection margin is reached. An assistant holds forceps ready to clip vessels as they become visible so that dissection can proceed rapidly. Branches of the pudendal artery will require attention as they are encountered postero-laterally.",
"   </p>",
"   <p>",
"    It is important to avoid damaging the anal sphincter, while at the same time ensuring an adequate margin around a tumor placed posteriorly on the vulva or perineum. A finger in the rectum helps to guide the operator under these circumstances. As with a total vulvectomy, the posterior margin of the specimen is elevated with forceps, which can be held by the assistants while dissection proceeds. If necessary, the anterior third of the anal sphincter can be removed with the specimen.",
"   </p>",
"   <p>",
"    Superiolaterally, if a triple-incision procedure is being performed, the subcutaneous tissues that contain the lymphatics extending toward the groins on each side are taken with the specimen by dissecting under the skin-bridge that is left between the vulvectomy and groin dissection. Superiorly, the dissection is carried down toward the clitoral attachments by sweeping the specimen off the periosteum of the pubic bones and the deep fascia until the clitoral attachments are reached (",
"    <a class=\"graphic graphic_picture graphicRef60136 graphicRef72966 \" href=\"UTD.htm?8/12/8392\">",
"     picture 2A-B",
"    </a>",
"    ). The suspensory ligament of the clitoris may be clamped, divided, and ligated at this point.",
"   </p>",
"   <p>",
"    The vaginal incision is now made circumferentially, ensuring that the required margin around the tumor is maintained. The tip of a scalpel or Kelly forceps is passed through the specimen in the midline to isolate the crura (",
"    <a class=\"graphic graphic_picture graphicRef82590 \" href=\"UTD.htm?0/27/436\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61321 \" href=\"UTD.htm?42/37/43605\">",
"     picture 4",
"    </a>",
"    ). They are held with forceps, divided, and underrun with absorbable sutures. The specimen is detached completely and hemostasis is secured with Bovie. Venous sinuses around the urethra and vaginal margin may be difficult to control without use of a running suture. The specimen is sent for histology with the orientation marked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases the wound can be closed primarily without resorting to special techniques. Care is taken to appose the skin above the urethral meatus to the residual skin of the mons pubis. Marker sutures may be inserted to assess the way in which the edges will come together. Closure may be facilitated following resection of posterior lesions if the residual vagina is mobilized off its lateral attachments and the rectum posteriorly.",
"   </p>",
"   <p>",
"    A suction drain with wide holes is inserted on one or both sides and brought out through the perineum (",
"    <a class=\"graphic graphic_picture graphicRef74101 \" href=\"UTD.htm?30/58/31649\">",
"     picture 5",
"    </a>",
"    ). Paraffin gauze is placed over the wounds and covered by a gauze dressing held in place by a diaper made out of a sterile disposable drape.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Postoperative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is kept on bed rest for the first two to three days of the initial postoperative period. Pneumatic calf compression, active leg movements, and subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    are recommended to minimize the risk of deep venous thrombosis and embolism.",
"   </p>",
"   <p>",
"    The suction drains are left in place for at least three days and a urethral catheter is used to drain the bladder until the patient is ambulatory. The wound is inspected daily to ensure continued healing and to detect early signs of infection. The perineum is cleansed with sterile saline after the first 48 hours and dried with a hair dryer. Sitz baths are begun a few days later.",
"   </p>",
"   <p>",
"    The patient is given a low residue diet and constipating agents for three days, particularly if the anal sphincter or rectum were repaired. Following this period, stool softeners are prescribed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some wound breakdown is common, but this usually heals with conservative management. If the wound has been closed with skin flaps and necrosis has occurred, the dead skin should be debrided.",
"    <span class=\"nowrap\">",
"     Hematomas/seromas,",
"    </span>",
"    although unusual if adequate drainage is maintained, may require evacuation. Signs of infection should prompt obtaining specimens for culture and instituting antibiotics. Urinary tract infection, thromboembolism, and osteitis pubis are additional potential complications.",
"   </p>",
"   <p>",
"    Late sequelae include stenosis of the vaginal introitus and pelvic organ prolapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANCILLARY PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional procedures, which depend upon the characteristics of the primary tumor, may be required to ensure complete excision of the carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Wider margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive areas of skin can be excised with the primary tumor. The methods available for closure of the resulting defect should be considered when planning the procedure. In the event of being unable to fashion flaps, the defect can be packed with povidone-iodine soaked gauze and then allowed to granulate, with careful postoperative nursing care.",
"   </p>",
"   <p>",
"    The most widely used supplementary method of closure is by skin flaps, which may be of the transposition type, such as the rhomboid flap (particularly useful for small posterior defects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/5\">",
"     5",
"    </a>",
"    ]), the anterior obturator artery perforator flap [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/6\">",
"     6",
"    </a>",
"    ], or myocutaneous flaps (eg, gracilis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/7\">",
"     7",
"    </a>",
"    ], rectus abdominis, and tensor fascia lata [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]) or one of several lotus petal flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Urethral surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the tumor involves the urethra, the distal 1 cm can be excised without affecting continence. The residual urethral mucosa is included in the closure.",
"   </p>",
"   <p>",
"    If any more than the distal 1 cm of the urethra must be excised, the patient will require an additional procedure to prevent urinary incontinence. In some women this will be an anterior exenteration with formation of neobladder. An alternative procedure in the palliative setting is inversion of the proximal residual urethra into the bladder. Through a suprapubic incision the space of Retzius is entered and the upper urethra and bladder neck are exposed (",
"    <a class=\"graphic graphic_figure graphicRef75915 \" href=\"UTD.htm?1/19/1331\">",
"     figure 2",
"    </a>",
"    ). A rubber drain is passed around the urethra, which is mobilized around with the bladder neck, and then transected and transfixed. The anterior bladder is opened through a midline incision and the upper urethra is inverted into the bladder using forceps. The edges of the inverted bladder neck exteriorly are approximated. The bladder incision is then closed with continuous suture around a suprapubic catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vaginectomy (partial or total)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent and site of vaginal involvement will dictate the amount of surgery required. Involvement of the lower lateral wall can be dealt with by resection as necessary. If the tumor involves the anterior or posterior walls of the vagina, care must be taken not to damage the bladder or rectum while achieving clear margins around the tumor. Involvement of extensive amounts of the vagina will require removal of the bladder or anorectum, depending upon the site of involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6885?source=see_link\">",
"     \"Vaginectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Excision of anus and distal rectum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several procedures have been described for the excision of tumor involving the anus and rectum. When the lesion just encroaches on the anus, or there is a suspicion of this encroachment, the anterior third of the anus and sphincter can be excised without major impact on continence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/11\">",
"     11",
"    </a>",
"    ]. The external anal sphincter is repaired with interrupted 0 polyglactin or polydioxanone sutures. For extra support of the sphincter mechanism, the distal limbs of the puborectalis may be plicated together anterior to the anus. The skin can be closed with rhomboid flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many cases, partial resection of the anus would be insufficient and anovulvectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/12\">",
"     12",
"    </a>",
"    ], anoproctectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/13\">",
"     13",
"    </a>",
"    ], or posterior exenteration can be used. Anoproctectomy is a more extensive procedure than anovulvectomy. Anovulvectomy with sigmoid colostomy is a useful procedure in older women because it is well tolerated and avoids the need for an extensive abdominal procedure in addition to the perineal procedure. The operation is performed in two stages. First, a sigmoid end colostomy is raised in the left iliac fossa. Two weeks later, in the perineal phase, the tumor is excised widely including the anus and lower rectum. The rectum is transected and left opening into the perineal wound. It is usually secured to the posterior edge of the residual vagina and to the skin margins. If necessary, the two phases may be performed during the same surgery, with the lower bowel being irrigated from above to clean away fecal material.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sigmoid colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure was traditionally performed using a midline abdominal incision, however, in many cases, it can now be carried out using a single circular incision (ie, \"trephine\") over the site of the intended colostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/14\">",
"     14",
"    </a>",
"    ] or by using a laparoscopic technique [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoperative bowel preparation is recommended and general, epidural, or spinal anesthesia can be used. The patient should be placed in the supine position in Allen stirrups. If a trephine colostomy is planned, a 24 French Foley catheter is inserted into the rectum. The balloon end is inflated to hold it in place and the external end is connected to the bellows used for sigmoidoscopy.",
"   </p>",
"   <p>",
"    For a trephine colostomy, a 1 inch circular incision is made in the skin of the abdomen at the site of the intended colostomy and the disc of skin is removed (",
"    <a class=\"graphic graphic_figure graphicRef55408 \" href=\"UTD.htm?24/15/24830\">",
"     figure 3",
"    </a>",
"    ). Using an electrocautery instrument on cutting current, the incision is taken down through the subcutaneous fat to the rectus sheath. The external oblique aponeurosis is incised obliquely in the line of the muscle fibers. The underlying internal oblique and transversus muscles are separated and the retractors inserted to expose the peritoneum. The peritoneum is picked up with hemostats and incised carefully. The intended stoma is gently stretched with the fingers to allow adequate room for the bowel.",
"   </p>",
"   <p>",
"    The descending colon and sigmoid are identified. Babcock forceps are applied and used to gently elevate the bowel through the stoma site until a window of mesentery is visible (",
"    <a class=\"graphic graphic_figure graphicRef62019 \" href=\"UTD.htm?39/33/40478\">",
"     figure 4",
"    </a>",
"    ). It may be difficult to identify the nature of the bowel loop raised, although the presence of tenia will confirm large bowel. Before incising the bowel, a soft bowel clamp is applied above and the rectum and sigmoid are inflated with air from below to confirm the identity of the distal and proximal bowel.",
"   </p>",
"   <p>",
"    A small window is made in the mesentery at the apex of the loop of bowel and widened enough to allow a gastrointestinal anastomosis (GIA) stapler gun to be inserted (",
"    <a class=\"graphic graphic_figure graphicRef52464 \" href=\"UTD.htm?42/12/43215\">",
"     figure 5",
"    </a>",
"    ). The bowel is transected, and the distal end is inspected for hemostasis and placed back within the abdomen.",
"   </p>",
"   <p>",
"    The proximal part is prepared for the stoma. The staple line is excised and discarded. The bowel is opened out and sutured to the skin with interrupted",
"    <span class=\"nowrap\">",
"     3/0",
"    </span>",
"    polyglactin or catgut mucocutaneous sutures.",
"   </p>",
"   <p>",
"    The laparoscopic technique entails placement of a 5 mm port at a convenient site away from the intended site of the colostomy for carbon dioxide distension and camera placement. The port would normally be placed in the left upper quadrant, at the umbilicus or right iliac fossa. The left iliac fossa and the suprapubic areas are best avoided in patients with carcinoma of the vulva. After visualization of the intraabdominal situation, additional 5 mm ports can be placed, if necessary, to effect mobilization of the sigmoid colon sufficient for the colostomy to be fashioned without tension. The procedure is then completed as for the trephine technique, although distension is not necessary for discrimination between the proximal and distal ends [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Anovulvectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;General, epidural, or spinal can be administered. The patient is placed in Allen stirrups in the modified ski position with the thighs abducted 45 degrees and flexed 45 degrees. It is important to position the patient so that her body extends over the end of the table to allow access behind the anus.",
"   </p>",
"   <p>",
"    The incision margins are marked with a pen. The exact extent of resection depends on the size of the tumor, but encompasses the anus. A number one polyglactin suture is inserted circumferentially around the anal margin, pulled tight, and tied to stop anal leakage and provide traction on the anal canal and rectum. The dissection differs from a radical vulvectomy only in the posterior part.",
"   </p>",
"   <p>",
"    Mayo scissors are used for dissection in the ischiorectal fossa. In the midline posteriorly the fascia of the anococcygeal raphe may be palpated and divided. The levator muscles are incised on both sides and the anus and lower rectum are freed laterally and posteriorly. The rectum is transected above the tumor together with the posterior vagina, usually after the rest of the surgical specimen has been mobilized. Skin flaps may be required to close the defect. During closure of the wound the rectal mucosa can be secured to the posterior vaginal edge and the perineal skin closure.",
"   </p>",
"   <p>",
"    Postoperative care is similar to that for women who have undergone radical vulvectomy. The patient will intermittently discharge a small amount of mucus from the rectum into the perineum, but this is not usually a problem. Occasionally the mucus may be retained in the residual rectum and requires release either digitally or by dilation of the perineal opening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Partial excision of pubic symphysis and ischial rami",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excision of the central part of the pubic symphysis or parts of the ischial pubic rami can be performed with the Gigli saw in cases of central involvement. The opinion of an orthopedist should be sought because of potential problems with pelvic stability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Groin node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groin node dissection is performed in some cases to assess nodes for evidence of metastasis, which may indicate the need for further therapy, and to help reduce the chance of recurrence of further metastasis. The groin nodes are the most important prognostic indicator in squamous cell carcinoma of the vulva [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/17\">",
"     17",
"    </a>",
"    ]. If cancer recurs in a previously undissected groin, the outlook is grim [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The practice of groin node dissection is controversial in the management of malignant melanoma, but is probably not indicated for primary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Superficial versus deep lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph drainage from the vulva rarely bypasses the superficial nodes (",
"    <a class=\"graphic graphic_figure graphicRef67561 \" href=\"UTD.htm?28/5/28754\">",
"     figure 6",
"    </a>",
"    ), so it has been suggested that a superficial node dissection is all that is required for most patients with small carcinomas, provided these nodes are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/19\">",
"     19",
"    </a>",
"    ]. Although no studies have compared the use of superficial versus superficial plus deep groin node dissection, a retrospective series suggested that groin relapse in patients with negative nodes on superficial inguinal lymphadenectomy was caused by metastatic disease in unresected inguinal nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/20\">",
"     20",
"    </a>",
"    ]. Since it has been shown that the deep lymph nodes can be removed relatively easily without extensively disrupting the deep fascia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/21\">",
"     21",
"    </a>",
"    ] and with minimal additional morbidity, they should probably be removed to minimize the risk of persistent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Operative procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;General, epidural, or spinal anesthesia is used. If the groin node dissection alone is to be performed, the patient is placed supine with the legs abducted 30 degrees and externally rotated. If the vulva is also to be removed, the patient is placed in Allen stirrups in the same position. The legs can be repositioned after the groin node dissection so that the hips and knees are flexed.",
"   </p>",
"   <p>",
"    Provided the groin nodes are clinically negative, the groin incision runs 2 cm below and parallel to the inguinal ligament starting 3 cm distal and medial to the anterior superior iliac spine and ending below the superficial inguinal ring (",
"    <a class=\"graphic graphic_figure graphicRef68359 \" href=\"UTD.htm?19/54/20335\">",
"     figure 7",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef61254 \" href=\"UTD.htm?21/32/22017\">",
"     picture 6",
"    </a>",
"    ). If there is concern for groin node metastases, an elliptical skin incision can be made in the same line so that this overlying segment of skin can be excised with the nodes.",
"   </p>",
"   <p>",
"    The incision is taken through the full thickness of the skin and 2 to 3 mm into the fat. Allis forceps are applied to the dermal surface of the upper skin incision to provide traction while Mayo scissors or scalpel are used to dissect down through the subcutaneous fat to expose the glistening fascia of the aponeurosis of the external oblique muscle 3 cm above the inguinal ligament (",
"    <a class=\"graphic graphic_picture graphicRef73401 \" href=\"UTD.htm?28/58/29601\">",
"     picture 7",
"    </a>",
"    ). Care must be taken not to dissect too close to the skin of the flaps because this will jeopardize the blood supply and may lead to flap necrosis. Scarpa's (superficial) fascia, when prominent, can occasionally be mistaken for the external oblique aponeurosis, but does not have the glistening silver color. Once the external oblique aponeurosis is identified, the fatty tissue containing the inguinal nodes can be dissected off easily so that the lower margin of the inguinal ligament is exposed.",
"   </p>",
"   <p>",
"    The caudal skin flap is now raised and dissection is taken down through the subcutaneous fat to the deep fascia of the thigh, approximately 6 cm from the inguinal ligament. Although the initial incision and dissection should span the entire length of the caudal flap, it is easier to identify the deep fascia at the lateral end. Once the deep fascia has been reached, dissection of the fatty bundle containing the groin nodes off the deep fascia is performed from lateral to medial (",
"    <a class=\"graphic graphic_picture graphicRef80521 \" href=\"UTD.htm?33/36/34368\">",
"     picture 8",
"    </a>",
"    ). Laterally, the circumflex iliac vessels need to be electrocauterized, but throughout the dissection care must be taken to control bleeding. A finger is passed beneath the round ligament as it exits from the superficial inguinal ring. Traction on the proximal end of the round ligament and the medial end of the groin node bundle facilitates the dissection of tissues containing lymphatic vessels leaving the vulva (",
"    <a class=\"graphic graphic_picture graphicRef50585 \" href=\"UTD.htm?12/10/12450\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The fatty nodal bundle is grasped with forceps and elevated by the operator or assistant. Anteromedially the great saphenous vein (GSV) is identified ascending into the thigh from the medial side. The vein can be left in situ, but it is generally easier to ligate and divide at the distal margin of the dissection.",
"   </p>",
"   <p>",
"    Following ligation of the GSV the tissues on the medial and caudal side are dissected from the deep fascia. The cranial end of the ligated GSV is followed down to the saphenofemoral junction. Although the pulsation of the femoral artery is a good landmark for identifying the position of the common femoral vein it is best approached by following down the medial side of the cranial end of the GSV. This end of the GSV is dissected free on all sides and the LGSV is ligated, transfixed, and divided approximately 0.5 to 1 cm from the saphenofemoral junction, taking care not to narrow the common femoral vein. The specimen is removed usually by dividing the lymphatic tissues entering the femoral canal.",
"   </p>",
"   <p>",
"    The deep femoral nodes may have been removed with the specimen but if not, residual tissue is dissected from the anterior and medial surfaces of the femoral vein above the lower limit of the fossa ovalis (",
"    <a class=\"graphic graphic_figure graphicRef74932 \" href=\"UTD.htm?36/23/37233\">",
"     figure 8",
"    </a>",
"    ). Any fatty tissue in the femoral canal is excised.",
"   </p>",
"   <p>",
"    If the deep fascia has been extensively removed to expose much of the femoral artery and vein in the floor of the femoral triangle, and especially following preoperative radiation, a sartorius muscle flap can be swung across to protect the femoral vessels. The muscle forms the lateral boundary of the femoral triangle running from the medial condyle of the tibia to the anterior superior iliac spine. A finger is passed underneath the belly of the upper part of the muscle and, using cutting Bovie, the muscle is divided close to the anterior superior iliac spine (",
"    <a class=\"graphic graphic_figure graphicRef62787 \" href=\"UTD.htm?12/37/12882\">",
"     figure 9",
"    </a>",
"    ). It is then swung across and sutured to the inguinal ligament just above the femoral vessels (",
"    <a class=\"graphic graphic_figure graphicRef60023 \" href=\"UTD.htm?10/28/10689\">",
"     figure 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Before closure, the skin flaps are checked to ensure that they are viable. If not, they need to be trimmed back to viable skin. The skin is closed with staples or interrupted vertical mattress sutures, ensuring that the skin edges are neatly apposed and everted. A suction drain is brought out laterally above the groin and secured. If a large defect is left, such as after radical resection of disease in the groin, the defect can be closed with a skin flap.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Postoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suction drainage is applied to allow time for the incision to heal and the underlying space to be obliterated. The drain can be removed once the wound has healed, even if significant volumes of lymph are still draining. The wound is kept dry but inspected for signs of necrosis or infection. The staples can be removed when the wound has healed cleanly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications of groin node dissection are wound infection, wound breakdown, and lymphedema. In one large series, these complications occurred in two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/22\">",
"     22",
"    </a>",
"    ]. The risk was highest in patients who had positive nodes, postoperative radiation therapy, or excision of the saphenous vein, and those who were over age 65.",
"   </p>",
"   <p>",
"    Intraoperative complications of groin node dissection are unusual, provided that care is taken with the dissection. A small tear in the femoral vein should be repaired with 5-0 prolene while a larger tear may require a patch from the residual GSV. Damage to the femoral artery will necessitate repair with 5-0 prolene. A divided inguinal ligament can be repaired with 0 polyglactin or prolene.",
"   </p>",
"   <p>",
"    It is not unusual for large volumes of lymph to collect in the drains. Infection can occur early or chronically and is usually responsive to antibiotics.",
"   </p>",
"   <p>",
"    A randomized trial that compared the used of fibrin sealant followed by sutured closure with standard sutured closure found no improvement in the development of lower extremity lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/23\">",
"     23",
"    </a>",
"    ]. Persistent lymphocyst is uncommon as usually the wound becomes adherent to the underlying tissues, obliterating the cavity that allows the fluid to collect. Repeated aspiration of lymphocysts may be attempted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=see_link&amp;anchor=H14#H14\">",
"     \"Complications of gynecologic surgery\", section on 'lymphedema and lymphocyst'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of chronic groin complications is correlated with the extent of lymph node dissection and whether postoperative radiation therapy was administered. Chronic swelling of the leg (lymphedema) may occur as a consequence of the dissection, particularly if performed in association with radiation therapy, and this may be associated with recurrent bouts of infection (lymphangitis). Infections can be treated with elevation and antibiotics, but the swelling may be less responsive to therapy. The patient can try compression stockings and elevation and may benefit from treatment at a lymphedema center. Anesthesia over the medial thigh also frequently occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The skin flaps may necrose partially or completely, particularly after radiation treatment. Dead tissue should be excised and the wound should be allowed to granulate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Sentinel node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of a sentinel inguinofemoral lymph node (SLN) may reduce the need for a complete inguinofemoral node dissection, and thus, reduce morbidity. This procedure is becoming the standard of care for identification of the status of the inguinofemoral lymph nodes. The rationale for this is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=see_link\">",
"     \"Vulvar cancer: Staging, treatment, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identification of the sentinel node is facilitated by the use of a combination of lymphoscintigraphy and vital dyes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/25\">",
"     25",
"    </a>",
"    ]. One to three hours before surgery approximately 2mCi of technetium 99m-labelled sulfur colloid in a volume of 1cc is injected intradermally around and in front of the leading edge of the vulvar carcinoma in the radiology department [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4936/abstract/26\">",
"     26",
"    </a>",
"    ]. Scintigraphy produces an image of signal from the sentinel node or nodes and their approximate anatomical site. At the time of surgery, 5 to 10 minutes prior to dissection of the groin, 1 to 3 mL of a vital blue dye such as isosulphan blue is injected intradermally around the leading edge of the tumor using an insulin-type syringe and fine-gauge needle (",
"    <a class=\"graphic graphic_picture graphicRef50585 \" href=\"UTD.htm?12/10/12450\">",
"     picture 9",
"    </a>",
"    ). The dye can usually be seen entering the lymphatics. The site of the groin incision is determined by use of a hand-held gamma probe which identifies the sentinel node based on its high count, usually at least 10x the basal count (",
"    <a class=\"graphic graphic_picture graphicRef76982 \" href=\"UTD.htm?41/63/42993\">",
"     picture 10",
"    </a>",
"    ). Care must be taken to point the probe slightly away from the tumor to avoid contamination from the peritumoral injection site. A 2 to 4 cm incision is made over the area and dissection takes place to identify the hot \"blue\" node assumed to be the sentinel node. Additional nodes identified as being possible sentinel nodes should be removed based on interpretation of the pre-operative lymphoscintigram together with the gamma probe and dye findings following removal of the initial node. If the sentinel node is not detected then a completed groin node dissection should be performed. The node(s) should be sent for frozen section so that if it is positive for metastatic disease the appropriate groin node dissection can be performed. If negative the wounds are closed with subcuticular suture without drainage (",
"    <a class=\"graphic graphic_picture graphicRef72566 \" href=\"UTD.htm?24/37/25168\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radical vulvectomy is a procedure usually performed for the treatment of vulvar carcinoma. Ancillary procedures performed with radical vulvectomy can include distal urethrectomy, vaginectomy, pubic symphysectomy, ano-vulvectomy, posterior exenteration, sigmoid colostomy and superficial and deep inguinal lymph node dissection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modifications to radical surgery have focused on limiting the extent of tissue removal and reducing the need for complete inguinal node dissections to reduce morbidity. Such modifications have included less radical resection of the cancer and the use of sentinel node sampling. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Radical vulvectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bladder and anal sphincter function may be preserved by limiting the extent of surgery and treating patients with chemotherapy or radiation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Operative procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Musculo-cutaneous transposition flaps may be necessary to close large defects on the vulva and perineum. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Operative procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/1\">",
"      WAY S. The anatomy of the lymphatic drainage of the vulva and its influence on the radical operation for carcinoma. Ann R Coll Surg Engl 1948; 3:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/2\">",
"      Heaps JM, Fu YS, Montz FJ, et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990; 38:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/3\">",
"      Preti M, Ronco G, Ghiringhello B, Micheletti L. Recurrent squamous cell carcinoma of the vulva: clinicopathologic determinants identifying low risk patients. Cancer 2000; 88:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/4\">",
"      Chan JK, Sugiyama V, Tajalli TR, et al. Conservative clitoral preservation surgery in the treatment of vulvar squamous cell carcinoma. Gynecol Oncol 2004; 95:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/5\">",
"      Helm CW, Hatch KD, Partridge EE, Shingleton HM. The rhomboid transposition flap for repair of the perineal defect after radical vulvar surgery. Gynecol Oncol 1993; 50:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/6\">",
"      O'Dey DM, Bozkurt A, Pallua N. The anterior Obturator Artery Perforator (aOAP) flap: surgical anatomy and application of a method for vulvar reconstruction. Gynecol Oncol 2010; 119:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/7\">",
"      Wheeless CR Jr, McGibbon B, Dorsey JH, Maxwell GP. Gracilis myocutaneous flap in reconstruction of the vulva and female perineum. Obstet Gynecol 1979; 54:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/8\">",
"      Chafe W, Fowler WC, Walton LA, Currie JL. Radical vulvectomy with use of tensor fascia lata myocutaneous flap. Am J Obstet Gynecol 1983; 145:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/9\">",
"      Horta R, Filipe R, Costa J, et al. Vertical rectus abdominis musculocutaneous flap: a good option for reconstruction of large inguinofemoral defects with exposure of the femoral vessels: brief report focusing on management of advanced vulvar carcinoma. Int J Gynecol Cancer 2011; 21:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/10\">",
"      Sawada M, Kimata Y, Kasamatsu T, et al. Versatile lotus petal flap for vulvoperineal reconstruction after gynecological ablative surgery. Gynecol Oncol 2004; 95:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/11\">",
"      Hoffman MS, LaPolla JP, Roberts WS, et al. Use of local flaps for primary anal reconstruction following perianal resection for neoplasia. Gynecol Oncol 1990; 36:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/12\">",
"      Grimshaw, RN, Ghazal, Aswad, S, Monaghan, JM. The role of ano-vulvectomy in locally advanced carcinoma of the vulva. Int J Gynecol Cancer 1991; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/13\">",
"      Adams J, Daly JW. Proctectomy combined with vulvectomy for carcinoma of the vulva. Obstet Gynecol 1979; 54:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/14\">",
"      Senapati A, Phillips RK. The trephine colostomy: a permanent left iliac fossa end colostomy without recourse to laparotomy. Ann R Coll Surg Engl 1991; 73:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/15\">",
"      Fuhrman GM, Ota DM. Laparoscopic intestinal stomas. Dis Colon Rectum 1994; 37:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/16\">",
"      Ludwig KA, Milsom JW, Garcia-Ruiz A, Fazio VW. Laparoscopic techniques for fecal diversion. Dis Colon Rectum 1996; 39:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/17\">",
"      Homesley HD, Bundy BN, Sedlis A, et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1991; 164:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/18\">",
"      Hacker NF. Current treatment of small vulvar cancers. Oncology (Williston Park) 1990; 4:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/19\">",
"      DiSaia PJ, Creasman WT, Rich WM. An alternate approach to early cancer of the vulva. Am J Obstet Gynecol 1979; 133:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/20\">",
"      Gonzalez Bosquet J, Magrina JF, Gaffey TA, et al. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol 2005; 97:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/21\">",
"      Micheletti L, Borgno G, Barbero M, et al. Deep femoral lymphadenectomy with preservation of the fascia lata. Preliminary report on 42 invasive vulvar carcinomas. J Reprod Med 1990; 35:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/22\">",
"      Gaarenstroom KN, Kenter GG, Trimbos JB, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 2003; 13:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/23\">",
"      Carlson JW, Kauderer J, Walker JL, et al. A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 110:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/24\">",
"      Karakousis CP, Emrich LJ, Rao U. Groin dissection in malignant melanoma. Am J Surg 1986; 152:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/25\">",
"      Levenback CF, van der Zee AG, Rob L, et al. Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol 2009; 114:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4936/abstract/26\">",
"      Oonk MH, van de Nieuwenhof HP, van der Zee AG, de Hullu JA. Update on the sentinel lymph node procedure in vulvar cancer. Expert Rev Anticancer Ther 2010; 10:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3280 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4936=[""].join("\n");
var outline_f4_52_4936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RADICAL VULVECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Operative procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Postoperative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANCILLARY PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Wider margins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Urethral surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vaginectomy (partial or total)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Excision of anus and distal rectum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sigmoid colostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Anovulvectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Partial excision of pubic symphysis and ischial rami",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Groin node dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Superficial versus deep lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Operative procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Postoperative management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Sentinel node biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3280\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3280|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/57/24465\" title=\"figure 1\">",
"      Incisions radical vulvectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/19/1331\" title=\"figure 2\">",
"      Bladder neck exposed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/15/24830\" title=\"figure 3\">",
"      Incision for sigmoid colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/33/40478\" title=\"figure 4\">",
"      Sigmoid pull through colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/12/43215\" title=\"figure 5\">",
"      Dividing bowel for colostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/5/28754\" title=\"figure 6\">",
"      Superfic inguinal lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/54/20335\" title=\"figure 7\">",
"      Incision inguinal node dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/23/37233\" title=\"figure 8\">",
"      Deep femoral lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12882\" title=\"figure 9\">",
"      Division of sartorius muscle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/28/10689\" title=\"figure 10\">",
"      Sartorius muscle flap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3280|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/4/30784\" title=\"picture 1\">",
"      Vulvar squamous carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/30/3555\" title=\"picture 2A\">",
"      Radical vulvectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/43/2739\" title=\"picture 2B\">",
"      Radical vulvectomy2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/27/436\" title=\"picture 3\">",
"      Radical vulvectomy3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/37/43605\" title=\"picture 4\">",
"      Radical vulvectomy4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/58/31649\" title=\"picture 5\">",
"      Radical vulvectomy completed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/32/22017\" title=\"picture 6\">",
"      Incision sites radic vulvectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/58/29601\" title=\"picture 7\">",
"      Aponeurosis ext oblique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/36/34368\" title=\"picture 8\">",
"      Dissection of the fatty nodal bundle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/10/12450\" title=\"picture 9\">",
"      Inguinal lymph nodes vulvectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/63/42993\" title=\"picture 10\">",
"      Vulvar sentinel node identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/37/25168\" title=\"picture 11\">",
"      Sutured groin incisions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=related_link\">",
"      Complications of gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=related_link\">",
"      Disorders of Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6885?source=related_link\">",
"      Vaginectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=related_link\">",
"      Vulvar cancer: Staging, treatment, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14535?source=related_link\">",
"      Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_52_4937="Pathogenesis of asthma";
var content_f4_52_4937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4937/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4937/contributors\">",
"     Mark Liu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4937/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4937/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4937/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/52/4937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"classic\" signs and symptoms of asthma are intermittent dyspnea, cough, and wheezing. This well-recognized syndrome is characterized by variable airflow limitation and by airway hyperresponsiveness, which represents an exaggerated contractile response of the airways to a variety of stimuli.",
"   </p>",
"   <p>",
"    Atopy, or the genetic predisposition to develop specific IgE antibodies directed against common environmental allergens, is the strongest identifiable risk factor for the development of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/1\">",
"     1",
"    </a>",
"    ]. While the association of asthma and atopy is undisputed, the pathways by which atopy is expressed as clinical asthma and by which asthma occurs in the absence of atopy are not as clearly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/1\">",
"     1",
"    </a>",
"    ]. Intrinsic abnormalities in airway smooth muscle function, airway remodeling in response to injury or inflammation, and interactions between epithelial and mesenchymal cells appear to modulate and add to the effects of airway inflammation in creating the clinical presentation of asthma.",
"   </p>",
"   <p>",
"    The inflammatory, physiologic, and structural factors that contribute to the pathogenesis of asthma will be reviewed here, focusing on aspects that aid in the understanding of the clinical presentation of asthma and its treatment.",
"   </p>",
"   <p>",
"    Discussions of the genetics, clinical risk factors (eg, atopy, allergen exposure, viral illness, gender, and smoking), diagnosis, and management of asthma are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10713?source=see_link\">",
"     \"Genetics of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"     \"Risk factors for asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AIRWAY INFLAMMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway biopsies obtained by bronchoscopy have demonstrated that inflammation in asthma generally involves the same cells that play prominent roles in the allergic response in the nasal passages and skin, whether the individual is atopic or not. This supports the belief that the consequences of mast cell activation, mediated by a variety of cells, cytokines, and other mediators, are key to the development of clinical asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6775?source=see_link\">",
"     \"Pathogenesis of allergic rhinitis (rhinosinusitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mast cell activation by allergen provides a good model for asthma and will be described in this section. Accumulated evidence suggests that the following sequence of events explains how inhalation of allergen leads to the early, or immediate, phase of airway inflammation, which is followed about six hours later by a late phase reaction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial allergen exposure is followed by elaboration of specific IgE antibodies. Regulation of specific IgE production appears related to an overexpression of Th2 type T cell responses relative to the Th1 type; this overexpression is likely due to a combination of genetic and environmental influences. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"       \"The adaptive cellular immune response\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After allergen specific IgE antibodies are synthesized and secreted by plasma cells, they bind to high-affinity receptors on mast cells (and basophils). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link\">",
"       \"The biology of IgE\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When an allergen is subsequently inhaled and comes into contact with mucosal mast cells, it cross links allergen-specific IgE antibodies on the mast cell surface; rapid degranulation and mediator release follow in a calcium dependent process. This is known as the early or immediate phase reaction, which is described in the next section. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"       \"Mast cell derived mediators\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Early and late phase reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In human studies of allergen bronchoprovocation, allergen inhalation by a sensitized individual leads to bronchoconstriction within several minutes. This is called the early response and correlates with the release of mast cell mediators during the immediate hypersensitivity reaction detailed above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/2\">",
"     2",
"    </a>",
"    ]. These mediators, including histamine, prostaglandin D2, and cysteinyl leukotrienes (LTC4, D4, and E4), contract airway smooth muscle (ASM) directly, and may also stimulate reflex neural pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This early phase reaction is sometimes followed by a late phase recurrence of bronchoconstriction several hours later. The late phase response coincides with an influx of inflammatory cells, including T lymphocytes, eosinophils, and basophils. The mediators released by these cells also cause ASM contraction that is largely reversible by beta-agonist administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the observation that beta-agonists do not completely reverse airflow obstruction caused by allergen inhalation is evidence that the late phase reaction is more complex than just ASM contraction.",
"   </p>",
"   <p>",
"    The late phase response is characterized by recruitment of inflammatory and immune cells, particularly the eosinophil, basophil, neutrophil, and helper, memory T-cells to sites of allergen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/2\">",
"     2",
"    </a>",
"    ]. Dendritic cells are also recruited to inflammatory sites and likely play important roles in mediating or modulating the response to allergen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/5\">",
"     5",
"    </a>",
"    ]. The roles of these various inflammatory cells are described in the next sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Eosinophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eosinophil is the most characteristic cell that accumulates in asthma and allergic inflammation; its presence is often related to disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/6\">",
"     6",
"    </a>",
"    ]. Activated eosinophils produce lipid mediators, such as leukotrienes and platelet activating factor, that mediate smooth muscle contraction; toxic granule products (eg, major basic protein, eosinophil-derived neurotoxin, eosinophil peroxidase, or eosinophil cationic protein) that can damage airway epithelium and nerves; and cytokines, such as granulocyte-macrophage colony stimulating factor (GM-CSF), transforming growth factors (TGF)-alpha and beta, and interleukins that may be involved in airway remodeling and fibrosis.",
"   </p>",
"   <p>",
"    Eosinophils are recruited or activated by the hematopoietin interleukin 5 (IL-5), by the eotaxin family of chemokines via the eosinophil-selective chemokine receptor CCR3, and by Toll-like receptors (TLR) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mast cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells are increased in number in asthmatic airways and may be found in close association with airway smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition to producing bronchoconstricting mediators (eg, histamine, certain prostaglandins, and leukotrienes), mast cells also store and release tumor necrosis factor (TNF)-alpha, which is important in the recruitment and activation of inflammatory cells and in altered function and growth of ASM [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"     \"Mast cell derived mediators\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=see_link\">",
"     \"Mast cells: Surface receptors and signal transduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H18#H18\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Anti-TNFa agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Th2 lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T cell population infiltrating the asthmatic airway is characterized by the T-helper 2 subset (Th2) of lymphocytes that produces a restricted panel of cytokines, including interleukin (IL)-3, IL-4, IL-5, IL-13, and granulocyte macrophage colony-stimulating factor (GM-CSF), but not interferon gamma, when stimulated with antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/13\">",
"     13",
"    </a>",
"    ]. Th2 lymphocytes also express the chemokine receptors (CCR4 and CCR8) and the chemoattractant receptor (CR)-like molecule (CRTH2), a receptor for prostaglandin D2 (PGD2), suggesting potential interactions between the mast cell and chemotactic signals that target eosinophils and Th2 cells and that sustain airway inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The actions of the following cytokines produced by Th2 lymphocytes strongly suggest that they play critical roles in asthma and allergic responses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-3 is a survival factor for eosinophils and basophils.",
"     </li>",
"     <li>",
"      IL-4 helps in the differentiation of uncommitted T cells into Th2 cells, switch of B-lymphocyte immunoglobulin synthesis to IgE production, and selective endothelial cell expression of vascular cell adhesion molecule-1 (VCAM-1) that mediates eosinophil, basophil, and T cell specific recruitment.",
"     </li>",
"     <li>",
"      IL-5 is the major hematopoietic cytokine regulating eosinophil production and survival.",
"     </li>",
"     <li>",
"      IL-13 appears to contribute to airway eosinophilia, mucous gland hyperplasia, airway fibrosis, and remodeling [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GM-CSF is also a survival factor for eosinophils.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the prominence of Th2 cytokines in asthma and allergic inflammation, pharmacologic interventions against IL-4 and IL-5 using recombinant biologic agents have failed to demonstrate consistent efficacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial positive responses in small trials of anti-IL-4 therapy using an inhaled, soluble IL-4 receptor to treat moderate persistent asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/19,20\">",
"       19,20",
"      </a>",
"      ] were not reproduced by further study (unpublished). A monoclonal antibody against the IL-4 receptor also failed to demonstrate efficacy in patients with moderate to severe asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/21\">",
"       21",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Initial clinical trials using anti-IL-5 monoclonal antibodies (SCH55700 and mepolizumab) in patients with asthma revealed no significant clinical improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. However, a study with mepolizumab administered to patients with prednisone-dependent eosinophilic asthma demonstrated a reduction in exacerbation frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/24\">",
"       24",
"      </a>",
"      ]. In addition, a trial of the anti-IL-5 antibody, reslizumab, in uncontrolled eosinophilic asthma demonstrated improved lung function and a trend toward better asthma control [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H20#H20\">",
"       \"Alternative and experimental agents for the treatment of asthma\", section on 'Anti-IL-5 antibodies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A trial of anti-IL-13 therapy with the monoclonal antibody, lebrikizumab, for 12 weeks in patients with asthma inadequately controlled on inhaled glucocorticoids, demonstrated significant improvements in lung function. The improvement occurred mainly in patients who had signs of increased IL-13 activity assessed by levels of periostin [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     NKT cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is hypothesized that invariant natural killer T (iNKT) cells direct or modulate asthma inflammation. iNKT cells express a conserved T-cell receptor (V[alpha]24&ndash;J[alpha]18), which is capable of recognizing glycolipid antigens, such as those from plant pollens. They rapidly produce both IL-4 and IL-13, which are involved in airway inflammation and IgE production.",
"   </p>",
"   <p>",
"    In one study, 63 percent of the CD4+ T lymphocytes in the airways of 14 patients with severe asthma were iNKT cells, compared to less than 1 percent in normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/27\">",
"     27",
"    </a>",
"    ]. However, this finding was not confirmed in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Basophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;While Th2 lymphocytes are a major source of the cytokines thought to participate in asthma, the basophil, in addition to producing histamine and leukotrienes, is a potent producer of IL-4 and IL-13, exceeding levels produced by T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Innate immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The innate immune system appears to play an important role in the development of allergic airway inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/30\">",
"     30",
"    </a>",
"    ]. Evidence for this includes the following key observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway epithelial cells express Toll-like receptors (TLR) on their surface, including TLR 4, a receptor that recognizes lipopolysaccharide (LPS). In addition to being a constituent of gram negative bacteria, LPS is a contaminant of inhalational allergens like house dust and animal dander. In a mouse model of asthma, inhalation of house dust extract appears to trigger airway epithelial cell TLR 4, leading to elaboration of the proallergenic cytokines IL-5, IL-13, IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dendritic cells, which form a network of innate immune cells within the airway, are increased in asthma and after allergen challenge [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/5,32\">",
"       5,32",
"      </a>",
"      ]. These cells are essential, not only to the initial induction of specific or adaptive immunity due to their role in antigen processing and presentation, but also in the effector phase of response to allergen following host sensitization [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neutrophils are the predominant granulocyte in the airways of some patients with severe, glucocorticoid-dependent asthma, sudden fatal asthma, and asthma exacerbations [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. Their exact role in the pathogenesis of severe asthma is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, there is some correlation between intensity of airway inflammatory changes (eg, airway eosinophils) and disease severity. However, in certain circumstances, the intensity of allergic type inflammatory changes does not correlate with disease severity. For instance, in severe asthma, defined in part by its poor response to glucocorticoid therapy, neutrophil-predominant inflammation may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36278?source=see_link\">",
"     \"Severe asthma: Evidence for heterogeneity of the disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of which medications are effective or ineffective as treatments for asthma also enhance our understanding of the role of airway inflammation and mast cell mediators in the pathophysiology of asthma. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacologic studies have clearly confirmed important roles for IgE and leukotrienes in the physiologic changes that occur during both the immediate and late phase asthma responses.",
"     </li>",
"     <li>",
"      Clinical treatment with anti-IgE monoclonal antibodies, antihistamines, and leukotriene modifying agents blocks significant portions of both early and late phase responses to allergen [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatments that target asthma inflammation (eg, glucocorticoids, anti-IgE) block the late phase response and improve control of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/1,39-41\">",
"       1,39-41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link\">",
"       \"Anti-IgE therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The success of leukotriene-modifying therapies for asthma management provides validation that mast cells, basophils, and leukotrienes participate in chronic asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The fact that dramatic reductions in eosinophils with monoclonal antibodies to interleukin 5 did not lead to improved asthma control underscores the complexity of asthma pathogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/22,23,44\">",
"       22,23,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EPITHELIAL-MESENCHYMAL CONTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternate paradigm for asthma pathogenesis has been proposed in which the \"epithelial-mesenchymal trophic unit\" plays a central role in inflammation and remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/45\">",
"     45",
"    </a>",
"    ]. According to this theory, structural cells, particularly bronchial epithelial cells, fibroblasts, smooth muscle, and vascular endothelial cells, elaborate mediators and cytokines that contribute to inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    airway remodeling. In this view, epithelial dysfunction and Th2 mediated inflammation serve as parallel pathways for proliferative signals to smooth muscle, fibroblasts, vessels, and nerves that collaborate to cause airway remodeling via interconnected chemokine and cytokine signals.",
"   </p>",
"   <p>",
"    Evidence for epithelial-mesenchymal communication in asthma includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Release of pro-fibrogenic and proliferative growth factors by bronchial epithelial cells is increased in asthma; these factors (eg, fibroblast growth factor (FGF-2), insulin-like growth factor (IGF-1), platelet-derived growth factor (PDGF), endothelin (ET-1), and transforming growth factor (TGF)-beta2) act on smooth muscle cells and fibroblasts to enhance matrix deposition (",
"      <a class=\"graphic graphic_figure graphicRef51543 \" href=\"UTD.htm?38/47/39671\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an animal model, IL-13 caused enhanced production of TGF-beta2 by epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/47\">",
"       47",
"      </a>",
"      ]. TGF-beta2 may promote fibroblast to myofibroblast differentiation, collagen production, and elaboration of additional growth factors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epidermal growth factor receptor (EGFR) expression is increased in asthmatic airway epithelium and correlates with subbasement membrane thickness [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Matrix metalloproteinase-9 expression is enhanced in the sub-basement membrane in patients with severe asthma and support ongoing damage and repair responses contributing to airway remodeling [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The finding of increased mast cells within airway smooth muscle in asthma suggests that the asthmatic smooth muscle itself may promote mast cell proliferation. Both airway smooth muscle cells and fibroblasts can produce c-kit ligand or stem cell factor (SCF), a growth factor for mast cells [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Th2 cytokines, IL-4 and IL-13 may also influence mesenchymal function by increasing release of TGF-beta2 from the epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/45,52\">",
"       45,52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF AIRFLOW OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable narrowing of the airway lumen causing variable reductions in airflow is a pathognomonic feature of asthma. Mechanisms causing airflow limitation include contraction of airway smooth muscle, thickening of the airway wall due to edema or cellular components, plugging of airways with mucus or cellular debris, and airway remodeling. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Airway remodeling'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Smooth muscle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraction and relaxation of airway smooth muscle (ASM) accounts for much of the rapid changes in airflow limitation characterizing asthma and is the basis for beta-agonist therapy that directly relaxes ASM. Bronchoconstriction may be due to direct effects of contractile agonists released from inflammatory cells or reflex neural mechanisms. As an example, mast cell and eosinophil mediators, such as leukotrienes C4, D4, and E4 and histamine, are potent bronchoconstrictors.",
"   </p>",
"   <p>",
"    Airway inflammation occurs throughout the tracheobronchial tree; varying degrees of obstruction of different diameter airways may determine disease physiology. In theory, obstruction in large airways leads to airflow limitation and decreased flow rates, while obstruction in small airways (ie, diameter less than 2 mm) leads to airway closure at low lung volumes, air trapping with an increase in residual volume, and in many cases, dynamic hyperinflation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/53\">",
"     53",
"    </a>",
"    ]. Hyperinflation may compensate for airway narrowing by increasing the tethering forces of the lung parenchyma that oppose airway narrowing at increasing lung volumes, a phenomenon known as airway-parenchymal interdependence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If airway obstruction is widespread, dynamic hyperinflation is more likely to lead to increases in total lung capacity (TLC); less widespread obstruction is less likely to increase TLC, but may cause local areas of hyperinflation. Much of the chest tightness and discomfort of an asthma attack may be due to air trapping and breathing at higher lung volumes to maintain airway patency and sustain adequate ventilation.",
"   </p>",
"   <p>",
"    The relative contributions of small and large airways to airflow obstruction have also been evaluated. Marked (sevenfold) increases in resistance in small airways have been documented in patients with mild asthma, despite normal spirometry; the small airways appear to be a key site of airway closure due to ASM contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/53,55\">",
"     53,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the notion that the small airways are the predominant site of airway narrowing in asthma has been challenged by imaging studies in patients with asthma. These studies suggest that even large airways can close with ASM contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/56\">",
"     56",
"    </a>",
"    ]. Studies using high resolution computed tomography (HRCT) in patients with asthma found heterogeneous narrowing of large airways often with recurring patterns of airway narrowing within individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/57\">",
"     57",
"    </a>",
"    ]. By hyperpolarized helium nuclear magnetic resonance imaging of asthmatic lungs, wedge-shaped ventilation defects were demonstrated consistent with narrowing or closure of segmental or subsegmental airways. The extent of these defects correlated with asthma severity and spirometry [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of bronchial thermoplasty, a technique that applies radiofrequency waves to the airways during bronchoscopy to decrease large airway smooth muscle mass, provide another line of evidence supporting a central role for ASM in large airways in the pathogenesis of asthma. Preliminary evidence suggests that reducing ASM mass by this technique improves asthma control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H30#H30\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Bronchial thermoplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bronchial hyperresponsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial hyperresponsiveness (BHR) is another defining feature of asthma and is a manifestation of reversible airflow obstruction due to smooth muscle contraction. BHR represents an exaggerated constrictor response to a variety of physical, chemical, or environmental stimuli. BHR can be quantitated by the dose response to pharmacologic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    or histamine, causing a 20 percent fall in FEV1. While BHR is not specific for asthma, patients with asthma typically demonstrate BHR to much lower doses (eg, 10- to 100-fold) of these agents than normal or allergic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While ASM is clearly involved in BHR, the precise mechanism that causes ASM to become hyperresponsive is not known. Possible explanations for BHR include alterations in smooth muscle function or mass, loss of airway-parenchymal interdependence, loss of a bronchodilating effect of deep breaths, enhanced sensitivity of neural pathways leading to bronchoconstriction, and exaggerated airway narrowing from smooth muscle contraction as a consequence of remodeling and structural abnormalities of the airway.",
"   </p>",
"   <p>",
"    Evidence that BHR in asthmatics is not due to altered ASM function or sensitivity, but rather to the breathing pattern in which the smooth muscle contracts, comes from studies that reproduce BHR in normals simply by prohibiting deep breaths during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/60\">",
"     60",
"    </a>",
"    ]. Under these conditions, the dose response to methacholine of normals was identical to that of asthmatics, indicating that the defect in asthma was loss of smooth muscle relaxation associated with deep inspiration. Acute airway narrowing in normal subjects could be demonstrated by HRCT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/61\">",
"     61",
"    </a>",
"    ]. Further, HRCT imaging of airways revealed equal bronchodilation in normals and asthmatics with deep inspiration. However, after airway constriction with methacholine, normal subjects maintained bronchodilation after a deep breath, while asthmatics constricted further [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible clinical manifestation of the loss of bronchodilator effect from deep inspiration is the bronchoconstriction that occurs during exercise in patients with asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;BHR presents clinically with the sudden onset of shortness of breath following inhalation of irritants or cold air. Patients may describe the sensation that their airways feel \"twitchy\", meaning that minor changes in the inhaled air can lead to need for their beta agonist inhaler. Beta agonists cause smooth muscle relaxation at least temporarily. This sensation of \"twitchiness\" may occur when airway inflammation is present and may be improved by allergen and irritant avoidance or treatment of inflammation with glucocorticoids. Better understanding of the physiology of this response may lead to better methods for treatment and prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     AIRWAY REMODELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many patients have intermittent asthma symptoms and normal physiologic testing between asthma episodes, increasing evidence suggests that a subset of patients with asthma have irreversible airflow obstruction, which is believed to be caused by airway remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/63\">",
"     63",
"    </a>",
"    ]. Airway remodeling refers to structural changes in the airways that may cause irreversible airflow limitation, superimposed on the effects of inflammation and smooth muscle contraction described above (",
"    <a class=\"graphic graphic_figure graphicRef51543 \" href=\"UTD.htm?38/47/39671\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic changes of airway remodeling include damage or loss of the normal pseudostratified structure of airway epithelium, an increase in the proportion of mucous-producing goblet cells, fibrotic thickening of the sub-epithelial reticular basement membrane or \"lamina reticularis\", increased numbers of myofibroblasts, increased vascularity, increased airway smooth muscle mass, and increased extracellular matrix.",
"   </p>",
"   <p>",
"    Such structural changes contribute to bronchial wall thickening, alterations in the physiologic consequences of smooth muscle contraction, or loss of airway-parenchymal interdependence (ie, the tethering forces exerted by the lung parenchyma that maintain airway patency). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Smooth muscle'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Contribution of airway remodeling to bronchial hyperresponsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural narrowing of airways associated with remodeling appears to increase BHR. This was examined in a study that correlated pulmonary function test parameters with the dimensions of small, medium, and large airways measured by HRCT in 21 subjects with moderate or severe asthma (baseline forced expiratory volume in 1 second (FEV1) was 64 percent of predicted) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/64\">",
"     64",
"    </a>",
"    ]. Airway dimensions, measured at total lung capacity (TLC) and functional residual capacity (FRC), were analyzed for relationships to lung volumes at baseline and after intensive bronchodilator treatment. The change between findings at baseline and after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    was felt to reflect the effect of airway smooth muscle tone and structure, respectively. The following findings suggest that dynamic hyperinflation caused by narrowing of large airways (ie, remodeling) is a major determinant of bronchial hyperresponsiveness in asthma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline smooth muscle tone was associated with an increased residual volume (RV) that was threefold greater than the decrease in forced vital capacity (FVC) due to a simultaneous increase in TLC.",
"     </li>",
"     <li>",
"      The increase in RV correlated inversely with the relaxed luminal diameter of medium airways and directly with the wall thickness of large airways under conditions where smooth muscle tone was absent, not with the degree of smooth muscle tone or dimensions of small airways.",
"     </li>",
"     <li>",
"      Decreased FVC was the major determinant of baseline FEV1. Whether or not TLC increased and FVC fell, was also dependent on the dimensions of relaxed large airways, with narrower large airways correlating with larger falls in FVC and FEV1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical correlation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway remodeling is thought to be an early feature of asthma based on the description of sub-basement membrane thickening in the airways of children with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/65\">",
"     65",
"    </a>",
"    ]. In adults, evidence for remodeling comes from the observation that many adults with asthma have an irreversible component to their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/66\">",
"     66",
"    </a>",
"    ]. The general consensus is that patients with more severe and earlier onset asthma experience accelerated loss of lung function due to airway remodeling; however, the extent of progression and loss of lung function is highly variable.",
"   </p>",
"   <p>",
"    Longitudinal studies have demonstrated progressive loss of lung function in subjects with asthma compared to normals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. However, other studies have suggested that this depends on the severity of asthma; patients with mild asthma were less likely to manifest airway",
"    <span class=\"nowrap\">",
"     remodeling/worsening",
"    </span>",
"    airflow limitation, whereas those with severe asthma were more likely to show evidence of airway remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. As an example, a study from Melbourne, Australia, that followed a large cohort of asthmatic and control subjects for 35 years, did not find accelerated average decline in lung function with asthma; however, those with severe asthma had progressive disease through childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/69\">",
"     69",
"    </a>",
"    ]. Adults with low lung function had developed low lung function in childhood, suggesting that the abnormality was present early and persisted over time. In a study that used computed tomography (CT) to assess airway wall thickness, patients with severe asthma had thicker airway walls than those with mild asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of this feature of asthma is that remodeling may be an early component of asthma pathogenesis and patients who are prone to remodeling may need a different approach to treatment than those who are not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MODULATORY FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors appear to influence whether susceptible individuals progress to overt asthma. These include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern genetic techniques have identified genes that may contribute to the pathogenesis of asthma through the above described mechanisms or through unidentified pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10713?source=see_link\">",
"     \"Genetics of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental exposure to air pollution, allergens (eg, dust mite, occupational allergens), cigarette smoke, and endotoxin have all been associated with an increased risk of asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link\">",
"     \"Risk factors for asthma\"",
"    </a>",
"    .) It is hypothesized that interactions between genetic susceptibility and exposure to certain inflammatory, infectious, or irritant agents determine who will develop symptomatic asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infectious agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both bacterial and viral respiratory tract infections have been associated with increased risk of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4937/abstract/71\">",
"     71",
"    </a>",
"    ]. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H17#H17\">",
"     \"Risk factors for asthma\", section on 'Respiratory infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exact mechanisms by which these factors increase the risk of asthma are still under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While the clinical syndrome of asthma is common and easily recognized, the pathogenesis of asthma involves complex interactions between inflammatory and resident airway cells. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mast cells, eosinophils, lymphocytes, and their associated products appear especially prominent in the airways of patients with asthma. Inflammatory events and associated alterations in airway smooth muscle function result in asthma symptoms, and also in structural changes, particularly within the epithelium, subepithelium, fibroblasts, and smooth muscle. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Airway inflammation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchial hyperresponsiveness (BHR) is a defining feature of asthma and is a manifestation of exaggerated reversible airway obstruction due to smooth muscle contraction. Several theories are being explored to explain this phenomenon. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bronchial hyperresponsiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Structural cells, particularly the epithelium, fibroblasts, smooth muscle, and endothelium, may contribute to inflammation or airway remodeling through elaboration of mediators and cytokines. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Airway remodeling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of genetic, environmental, and infectious factors appear to modulate whether susceptible individuals progress to overt asthma. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Modulatory factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Improved understanding of these relationships will lead to new interventions for asthma by targeting key components of airway inflammation and remodeling.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report II: Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute (NIH publication no. 97-4051), Bethesda, MD 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/2\">",
"      Liu MC, Hubbard WC, Proud D, et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis 1991; 144:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/3\">",
"      Riccio MM, Proud D. Evidence that enhanced nasal reactivity to bradykinin in patients with symptomatic allergy is mediated by neural reflexes. J Allergy Clin Immunol 1996; 97:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/4\">",
"      Peebles RS Jr, Permutt S, Togias A. Rapid reversibility of the allergen-induced pulmonary late-phase reaction by an intravenous beta2-agonist. J Appl Physiol 1998; 84:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/5\">",
"      Jahnsen FL, Moloney ED, Hogan T, et al. Rapid dendritic cell recruitment to the bronchial mucosa of patients with atopic asthma in response to local allergen challenge. Thorax 2001; 56:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/6\">",
"      Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/7\">",
"      Wong CK, Cheung PF, Ip WK, Lam CW. Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol 2007; 37:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/8\">",
"      Brightling CE, Bradding P, Symon FA, et al. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/9\">",
"      Nakae S, Ho LH, Yu M, et al. Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. J Allergy Clin Immunol 2007; 120:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/10\">",
"      Stewart AG, Tomlinson PR, Fernandes DJ, et al. Tumor necrosis factor alpha modulates mitogenic responses of human cultured airway smooth muscle. Am J Respir Cell Mol Biol 1995; 12:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/11\">",
"      Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/12\">",
"      Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/13\">",
"      Robinson DS. The role of the T cell in asthma. J Allergy Clin Immunol 2010; 126:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/14\">",
"      Mikhak Z, Fukui M, Farsidjani A, et al. Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation. J Allergy Clin Immunol 2009; 123:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/15\">",
"      Xue L, Gyles SL, Wettey FR, et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol 2005; 175:6531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/16\">",
"      Gyles SL, Xue L, Townsend ER, et al. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants. Immunology 2006; 119:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/17\">",
"      Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/18\">",
"      Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012; 130:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/19\">",
"      Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/20\">",
"      Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/21\">",
"      Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/22\">",
"      Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/23\">",
"      Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/24\">",
"      Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/25\">",
"      Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/26\">",
"      Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/27\">",
"      Akbari O, Faul JL, Hoyte EG, et al. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med 2006; 354:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/28\">",
"      Vijayanand P, Seumois G, Pickard C, et al. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N Engl J Med 2007; 356:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/29\">",
"      Redrup AC, Howard BP, MacGlashan DW Jr, et al. Differential regulation of IL-4 and IL-13 secretion by human basophils: their relationship to histamine release in mixed leukocyte cultures. J Immunol 1998; 160:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/30\">",
"      Holgate ST. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol 2007; 28:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/31\">",
"      Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009; 15:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/32\">",
"      Tunon-De-Lara JM, Redington AE, Bradding P, et al. Dendritic cells in normal and asthmatic airways: expression of the alpha subunit of the high affinity immunoglobulin E receptor (Fc epsilon RI -alpha). Clin Exp Allergy 1996; 26:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/33\">",
"      van Rijt LS, Jung S, Kleinjan A, et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med 2005; 201:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/34\">",
"      Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/35\">",
"      Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/36\">",
"      Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 1993; 148:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/37\">",
"      Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/38\">",
"      Roquet A, Dahl&eacute;n B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/39\">",
"      Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/40\">",
"      Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/41\">",
"      Djukanovi R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/42\">",
"      Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/43\">",
"      Liu MC, Dub&eacute; LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol 1996; 98:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/44\">",
"      Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/45\">",
"      Holgate ST, Davies DE, Lackie PM, et al. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000; 105:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/46\">",
"      Zhang S, Smartt H, Holgate ST, Roche WR. Growth factors secreted by bronchial epithelial cells control myofibroblast proliferation: an in vitro co-culture model of airway remodeling in asthma. Lab Invest 1999; 79:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/47\">",
"      Richter A, Puddicombe SM, Lordan JL, et al. The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001; 25:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/48\">",
"      Hackett TL, Warner SM, Stefanowicz D, et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. Am J Respir Crit Care Med 2009; 180:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/49\">",
"      Puddicombe SM, Polosa R, Richter A, et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 2000; 14:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/50\">",
"      Wenzel SE, Balzar S, Cundall M, Chu HW. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol 2003; 111:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/51\">",
"      Kassel O, Schmidlin F, Duvernelle C, et al. Human bronchial smooth muscle cells in culture produce stem cell factor. Eur Respir J 1999; 13:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/52\">",
"      Mullings RE, Wilson SJ, Puddicombe SM, et al. Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. J Allergy Clin Immunol 2001; 108:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/53\">",
"      Mitchell HW, Sparrow MP. Increased responsiveness to cholinergic stimulation of small compared to large diameter cartilaginous bronchi. Eur Respir J 1994; 7:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/54\">",
"      Adler A, Cowley EA, Bates JH, Eidelman DH. Airway-parenchymal interdependence after airway contraction in rat lung explants. J Appl Physiol 1998; 85:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/55\">",
"      Wagner EM, Liu MC, Weinmann GG, et al. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990; 141:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/56\">",
"      Brown RH, Mitzner W. The myth of maximal airway responsiveness in vivo. J Appl Physiol 1998; 85:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/57\">",
"      King GG, Carroll JD, M&uuml;ller NL, et al. Heterogeneity of narrowing in normal and asthmatic airways measured by HRCT. Eur Respir J 2004; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/58\">",
"      de Lange EE, Altes TA, Patrie JT, et al. Evaluation of asthma with hyperpolarized helium-3 MRI: correlation with clinical severity and spirometry. Chest 2006; 130:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/59\">",
"      Liu MC, Bleecker ER, Lichtenstein LM, et al. Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis 1990; 142:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/60\">",
"      Skloot G, Permutt S, Togias A. Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. J Clin Invest 1995; 96:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/61\">",
"      Brown RH, Croisille P, Mudge B, et al. Airway narrowing in healthy humans inhaling methacholine without deep inspirations demonstrated by HRCT. Am J Respir Crit Care Med 2000; 161:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/62\">",
"      Brown RH, Scichilone N, Mudge B, et al. High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma. Am J Respir Crit Care Med 2001; 163:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/63\">",
"      Limb SL, Brown KC, Wood RA, et al. Irreversible lung function deficits in young adults with a history of childhood asthma. J Allergy Clin Immunol 2005; 116:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/64\">",
"      Brown RH, Pearse DB, Pyrgos G, et al. The structural basis of airways hyperresponsiveness in asthma. J Appl Physiol 2006; 101:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/65\">",
"      Barbato A, Turato G, Baraldo S, et al. Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med 2006; 174:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/66\">",
"      ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/67\">",
"      Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/68\">",
"      Grol MH, Gerritsen J, Vonk JM, et al. Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years. A 30-year follow-up study. Am J Respir Crit Care Med 1999; 160:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/69\">",
"      Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol 2002; 109:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/70\">",
"      Aysola RS, Hoffman EA, Gierada D, et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008; 134:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4937/abstract/71\">",
"      Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 2007; 357:1487.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 522 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-E86EC8C0B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4937=[""].join("\n");
var outline_f4_52_4937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AIRWAY INFLAMMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Early and late phase reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Eosinophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mast cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Th2 lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NKT cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Basophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Innate immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical correlation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EPITHELIAL-MESENCHYMAL CONTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PHYSIOLOGY OF AIRFLOW OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Smooth muscle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bronchial hyperresponsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical correlation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      AIRWAY REMODELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Contribution of airway remodeling to bronchial hyperresponsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical correlation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MODULATORY FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infectious agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/522\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/522|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/47/39671\" title=\"figure 1\">",
"      Airway remodeling",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10713?source=related_link\">",
"      Genetics of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=related_link\">",
"      Mast cell derived mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=related_link\">",
"      Mast cells: Surface receptors and signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6775?source=related_link\">",
"      Pathogenesis of allergic rhinitis (rhinosinusitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36278?source=related_link\">",
"      Severe asthma: Evidence for heterogeneity of the disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_52_4938="Acute renal allograft rejection: Treatment";
var content_f4_52_4938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute renal allograft rejection: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4938/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4938/contributors\">",
"     W James Chon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4938/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4938/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4938/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/52/4938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/52/4938/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/52/4938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the use of potent immunosuppressive agents immediately following and in the maintenance phase after renal transplantation, the incidence of acute rejection, generally defined as rejection within the first year following transplantation, has fallen dramatically over time. With current immunosuppressive protocols, acute rejection rates below 15 percent are achieved in many centers and below 10 percent in some centers. Overall, only 13 percent of kidney transplant recipients in 2003 required therapy for acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When acute rejection occurs, it is an important clinical problem. As an example, the relative risk for transplant failure associated with an acute rejection episode has increased from 1.7 in 1988 to 5.2 in 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early episodes (occurring within 60 days of engraftment) may have a major effect on allograft survival. Some of these kidneys will not regain function even with maximal antirejection therapy. Kidneys that recover function may still have a decreased survival when compared to rejection-free kidneys, especially if the serum creatinine concentration does not return to near baseline levels.",
"   </p>",
"   <p>",
"    Acute rejection episodes are also the major predictor of the occurrence of chronic allograft nephropathy, which is responsible for most death-censored graft loss after the first year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link&amp;anchor=H12#H12\">",
"     \"Chronic renal allograft nephropathy\", section on 'Importance of acute rejection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of acute rejection of the renal allograft will be reviewed here. The diagnosis of acute rejection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25946?source=see_link\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INADEQUATE IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever acute rejection is confirmed, the possibility of inadequate immunosuppression, whether due to inadequate dosing or non-compliance, must be addressed. The failure to recognize this contributing factor increases the risk of continued acute rejection episodes and, due to inadequate long-term immunosuppression, may eventually lead to graft failure. In addition, the timely recognition and correction of such variables is an integral component of the Continuous Quality Improvement (CQI) process.",
"   </p>",
"   <p>",
"    Situations that lead to inadequate immunosuppression and an increased risk of rejection include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overzealous weaning of medications, typically corticosteroids. However, with the use of potent induction agents, such as Thymoglobulin&reg;, low rates of acute rejection have been reported with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      avoidance or minimization with early withdrawal trials [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Failure to recognize the administration of drugs that promote cytochrome P450 metabolism, leading to a decline in effective drug exposure to target sites. This is a principal concern with the agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      . (See",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?37/62/38880?source=see_link\">",
"       \"Cyclosporine: Patient drug information\"",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       \"Tacrolimus: Pediatric drug information\"",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=see_link\">",
"       \"Sirolimus: Patient drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inadequate dosing of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil. This may occur in people with a large body-mass index and possibly in African Americans who appear to require higher doses to achieve the same level of protection afforded non-African American allograft recipients who are administered lower doses [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. This is despite one study demonstrating that the pharmacokinetics of MMF do not differ by race or gender [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Noncompliance with medications. This may be due to the inability to tolerate side effects or to financial constraints imposed by high pharmaceutical costs among the under- or uninsured. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36517?source=see_link\">",
"       \"Psychiatric aspects of organ transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the treatment of established acute rejection include pulse corticosteroids, antibodies (monoclonal or polyclonal), manipulation of baseline immunosuppression,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other therapies. Treatment also depends on whether the rejection is a cellular rejection episode, an humorally mediated rejection or mixed (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25946?source=see_link\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A 2006 systematic review evaluated trials that assessed the efficacy of antibody versus other therapies for the treatment of acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/8\">",
"     8",
"    </a>",
"    ]. Compared with steroids, antibodies more effectively reversed a first acute rejection (RR of 0.57, 95% CI 0.38-0.87) and prevented allograft loss (RR of 0.74, 95% CI 0.58-0.95). With respect to resistant rejection, there was no benefit with OKT3 versus either antithymocyte globulin (ATG) or antilymphocyte globulin (ALG). However, this analysis is limited by the small size of trials, inadequate reporting of outcomes, and incomplete reporting of results, particularly concerning adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Banff classification of acute renal allograft rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best understand the strategy of treatment of acute renal allograft rejection, a review of the current Banff classification system is required. The following are the current diagnostic categories for the Banff classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10975968\">",
"    <span class=\"h3\">",
"     1. Normal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A histologically normal biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10975982\">",
"    <span class=\"h3\">",
"     2. Antibody-mediated changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;This may be concurrent with categories 3 to 6. It is due to documentation of circulating antidonor antibody, and C4d or allograft pathology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C4d deposition without morphologic evidence of acute rejection - This is characterized by C4d deposition, presence of circulating antidonor antibodies, and no signs of acute or chronic T cell mediated rejection or acute antibody-mediated rejection. Cases with simultaneous borderline changes or ATN are considered indeterminate.",
"     </li>",
"     <li>",
"      Acute antibody-mediated rejection - Histologic type (grade) include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type I &mdash; An acute tubular necrosis-like histology (C4d positive), with minimal inflammation",
"     </li>",
"     <li>",
"      Type II &mdash; A capillary-glomerulitis, with margination",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thromboses (C4d positive)",
"     </li>",
"     <li>",
"      Type III &mdash; Arterial-transmural",
"      <span class=\"nowrap\">",
"       inflammation/fibrinoid",
"      </span>",
"      changes (C4d positive)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic active antibody-mediated rejection - Histology involves glomerular double counters",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      multilayering of the peritubular capillary basement membrane",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interstitial",
"      <span class=\"nowrap\">",
"       fibrosis/tubular",
"      </span>",
"      atrophy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrous intimal thickening in arteries, (C4d positive).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10976039\">",
"    <span class=\"h3\">",
"     3. Borderline changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is suspicious for acute T cell mediated rejection. This category includes tubulitis foci (t1, t2, or t3, with i0 or i1) with no intimal arteritis present. However, the i2 t2 threshold for rejection is not met. This category may be concurrent with categories 2, 5, and 6.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10976054\">",
"    <span class=\"h3\">",
"     4. T--cell mediated rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;This may be concurrent with categories 2, 5, and 6.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute T cell mediated rejection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type IA &mdash; Significant interstitial inflammation (&gt;25 percent of parenchyma affected, i2 or i3) and foci moderate tubulitis (t2).",
"     </li>",
"     <li>",
"      Type IB &mdash; Significant interstitial inflammation (&gt;25 percent of parenchyma affected, i2 or i3) and severe tubulitis (t3)",
"     </li>",
"     <li>",
"      Type IIA &mdash; Mild to moderate arteritis (v1)",
"     </li>",
"     <li>",
"      Type IIB &mdash; Severe arteritis, which is associated with greater than 25 percent loss of the luminal area (v2)",
"     </li>",
"     <li>",
"      Type III &mdash; Transmural arteritis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arterial fibrinoid alterations, and necrosis of medial smooth muscle cells occurring in association with lymphocytic inflammation of the vessel (v3)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic active T-cell-mediated rejection - This is characterized by chronic allograft arteriopathy, which involves arterial intimal fibrosis with mononuclear cell infiltration in fibrosis and formation of neo-intima.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10976076\">",
"    <span class=\"h3\">",
"     5. Interstitial fibrosis and tubular atrophy, without evidence of any specific etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;This used to be termed chronic allograft nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &nbsp;I. Mild interstitial fibrosis and atrophy of tubules (&lt;25 percent of cortical area)",
"     </li>",
"     <li>",
"      &nbsp;II. Moderate interstitial fibrosis and atrophy of tubules (25 to 50 percent of cortical area)",
"     </li>",
"     <li>",
"      &nbsp;III. Severe interstitial fibrosis and atrophy of tubules (&gt;50 percent of cortical area)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10976083\">",
"    <span class=\"h3\">",
"     6. Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;This category consists of changes not thought to result from acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic rejection. It includes chronic hypertension, calcineurin inhibitor toxicity, chronic obstruction, pyelonephritis, and viral infections.",
"   </p>",
"   <p>",
"    In 2004, the proceedings of an NIH consensus conference were published concerning the assessment of antibody-mediated rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/11\">",
"     11",
"    </a>",
"    ]. The work group agreed that the diagnosis should also include allograft dysfunction, to distinguish clinical from subclinical rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10976098\">",
"    <span class=\"h2\">",
"     Major modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major modalities that have been used to treat acute cellular rejection include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulse corticosteroids",
"     </li>",
"     <li>",
"      Anti T-cell antibody therapies. This includes polyclonal antibodies, antithymocyte globulin (horse) and Thymoglobulin&reg; (rabbit), and monoclonal antibodies, OKT3.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonantibody rescue therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, have also been used.",
"   </p>",
"   <p>",
"    In 2006, the following frequency of use of the different agents in the United States was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticosteroids (73 percent)",
"     </li>",
"     <li>",
"      Antibody therapies (45 percent), with the most common being Thymoglobulin&reg; (34 percent), OKT3 (4 percent),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      (5 percent), daclizumab (1 percent), and ATGAM (1 percent)",
"     </li>",
"     <li>",
"      Antimetabolites (0.1 percent), with the most common being",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (0.1 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PULSE CORTICOSTEROIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first-line therapy for acute rejection in most centers is pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    given intravenously for three to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In addition to the intensification of maintenance immunosuppression therapy, such pulse corticosteroids are usually the only additional treatment added if the rejection is Banff class 1A or 1B (or CCTT class 1).",
"   </p>",
"   <p>",
"    After a steroid pulse, oral steroids are tapered rapidly to the same dosage the patient had been taking prior to the episode. The calcineurin inhibitor dose should be increased only if the serum levels prior to the episode of acute rejection were subtherapeutic. In addition, the dose of the antimetabolite may be increased empirically given that most centers do not measure levels.",
"   </p>",
"   <p>",
"    The expected reversal rate for the first episode of acute cellular rejection is 60 to 70 percent with this regimen. With successful response, the urine output increases and the serum creatinine starts decreasing within five days after initiating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evidence suggests that success with pulse corticosteroids may be enhanced by switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in those administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . The efficacy of this approach was evaluated in a study in which 119 patients treated with a cyclosporine-based regimen, after having been given pulse corticosteroids for a first rejection episode, were randomly assigned to an immediate switch to tacrolimus or to continue the cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/16\">",
"     16",
"    </a>",
"    ]. Successful resolution of the acute rejection episode was significantly more common with tacrolimus (93 versus 64 percent); in addition, it was associated with a significantly lower incidence of recurrent rejection at three months (9 versus 34 percent).",
"   </p>",
"   <p>",
"    The major complication of pulse steroids is increased susceptibility to infection, especially oral candidiasis. Other potential problems include acute hyperglycemia, hypertension, peptic ulcer disease, and psychiatric disturbances including euphoria and depression. Prophylactic H2 blockers as well as antifungal prophylaxis are generally recommended.",
"   </p>",
"   <p>",
"    Bone disease is also common in renal transplant recipients, with the most important risk factor being the loss of bone density due to the cumulative dose of steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/17\">",
"     17",
"    </a>",
"    ]. The highest steroid-associated rates of bone loss are in the first 3 to 12 months after transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Steroid resistance is defined as a lack of improvement in urine output or the plasma creatinine concentration within five to seven days. In this setting, second-line therapy consists of the administration of anti-lymphocyte antibodies, either as polyclonal anti-T cell antibodies, monoclonal OKT3, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Polyclonal antibodies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'OKT-3 (Anti-CD3 antibody)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Limited evidence suggests that assessment of the primary infiltrating cell line may be of benefit with cellular mediated steroid resistant rejection. Positive immunohistochemical staining with a majority of CD20 cells suggests a B cell rejection potentially responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/18\">",
"     18",
"    </a>",
"    ], while an infiltrate consisting primarily of CD68 indicates a monocyte rejection that may respond to high dose pulse steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/19\">",
"     19",
"    </a>",
"    ]. Further study is required to better understand the role of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POLYCLONAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyclonal anti T-cell antibodies are prepared by immunizing rabbits or horses with human lymphoid cells derived from the thymus (called antithymocyte globulin [ATG]) or cultured T cell lines. A disadvantage of using polyclonal ATG is the general recommendation to administer the medication via central venous access (due to the risk of phlebitis).",
"   </p>",
"   <p>",
"    ATG has been used both for prophylaxis against and for the primary treatment of acute rejection. The reversal rate has been between 75 and 100 percent in different series, with the plasma creatinine concentration returning to baseline several days to a week after initiating therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antithymocyte globulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;ATG induces T-lymphocyte depletion in the peripheral blood primarily by complement-dependent cell lysis; it also contains some B-cell specific antibodies inhibiting B cell proliferation and inducing B cell apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of ATG in treating acute rejection appears to vary according to the animal source of globulin. A direct comparison between Thymoglobulin&reg; (an ATG prepared from rabbits) and Atgam&reg; (an ATG prepared from horses) was performed in a multicenter, double-blind, randomized trial of 163 renal transplant recipients with acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/21\">",
"     21",
"    </a>",
"    ]. Compared to Atgam&reg;, thymoglobulin resulted in a higher rate of reversal of rejection (88 versus 76 percent) and a lower rate of recurrent rejection at 90 days after antibody therapy (17 versus 36 percent). Patient and graft survival, and the rates of adverse events and infections were similar between the two groups.",
"   </p>",
"   <p>",
"    During the period in which ATG is given, the doses of conventional immunotherapeutic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, are sometimes reduced to decrease the overall level of immunosuppression, thereby lowering the risk of infection. However, the widespread use of safe and effective antiviral and antimicrobial prophylaxis, particularly against cytomegalovirus infection and Pneumocystis carinii pneumonia, has rendered such an approach largely irrelevant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40084?source=see_link&amp;anchor=H5#H5\">",
"     \"Differential diagnosis of infection following renal transplantation\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever and chills may develop in some patients during the initial ATG infusion. Anaphylactic reactions, including respiratory distress and hypotension, are exceedingly rare. Pre-ATG administration of the concurrently given pulse steroids will prevent or significantly reduce infusion-related reactions. A pruritic skin rash (20 percent) and presumed antiplatelet antibody-induced thrombocytopenia of varying severity (50 percent) can occur in the course. Both CMV and herpes infections also may be seen, but are rarely life-threatening with current prophylactic antiviral therapy. Post-transplant lymphoproliferative disease (PTLD) may also be observed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to murine monoclonal antibodies (such as OKT3), ATG does not generally induce an effective host antibody response to the rabbit or horse serum. Thus, there is a greater opportunity for successful readministration. ATG has also been used to reverse rebound rejection following OKT3 administration in patients with high titers of anti-mouse antibodies, which limit retreatment with OKT3.",
"   </p>",
"   <p>",
"    ATG-induced serum sickness that responds to plasmapheresis has been reported in a number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. This includes one case with a rapidly progressive descending paralysis due to serum sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/22\">",
"     22",
"    </a>",
"    ]. Rapid improvement occurred with therapeutic plasmapheresis. Prior exposure to rabbits may increase the risk of development of serum sickness with the first course of rATG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MONOCLONAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibodies used in renal transplantation include OKT-3,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , daclizumab, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     OKT-3 (Anti-CD3 antibody)",
"    </span>",
"    &nbsp;&mdash;&nbsp;OKT3 was the first mouse antibody licensed for use in humans; it is directed against the CD3 antigen that is closely associated with the T cell receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/27\">",
"     27",
"    </a>",
"    ]. The principal mechanism of action of OKT3 is related to inhibition of cell-mediated immunity via",
"    <span class=\"nowrap\">",
"     modulation/clearing",
"    </span>",
"    of CD3+ T cells. OKT3 is no longer manufactured or available but because humanized anti-CD3 antibodies are in development, the following discussion is included for historical relevance.",
"   </p>",
"   <p>",
"    OKT3 has been used as the primary treatment of acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] and as rescue therapy for resistant rejection in kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/29\">",
"     29",
"    </a>",
"    ]. Currently, most centers use non-OKT3 agents when treating severe acute rejection, given the increased risk of severe reactions present with administration of OKT3 and the success demonstrated by ATG.",
"   </p>",
"   <p>",
"    The usual dose of OKT3 is 5 mg intravenously daily for 10 to 14 days. Monitoring of T cell subsets, specifically CD3 counts, can be utilized to individualize dosing. With the same caveats described above when administering ATG for acute rejection, the calcineurin inhibitor or the antimetabolite dose may be reduced during the OKT3 administration phase. Again, this is not commonly done with the availability of current anti-infective prophylactic agents.",
"   </p>",
"   <p>",
"    Although there have been reports suggesting that patients continued on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    during treatment with OKT3 may have worse ultimate allograft function, the issue of concurrent cyclosporine use remains unresolved. There are data, for example, showing that the anti-mouse antibody response induced by OKT3 may be diminished by a lower dose (50 percent) of cyclosporine compared to no therapy with cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The expected reversal rate with OKT3 is between 70 and 90 percent for steroid-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ATG-resistant rejection. The plasma creatinine concentration typically increases for the first two to three days of OKT3 therapy and then declines. However, rebound rejection occurs in approximately 50 percent of cases; roughly 75 percent of these episodes can be reversed by pulse steroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;OKT3 is associated with a number of important side effects that require careful monitoring after therapy. These include infection, lymphoproliferative disease associated with Epstein Barr virus, a first-dose reaction, pulmonary edema, and a hemolytic-uremic syndrome. It is critical that pulmonary edema be evaluated and treated, if necessary, prior to OKT3 administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Role in recurrent rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success rate of retreatment with OKT3 among renal transplant patients with recurrent episodes of acute rejection is related to its ability to",
"    <span class=\"nowrap\">",
"     modulate/clear",
"    </span>",
"    CD3+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/31\">",
"     31",
"    </a>",
"    ]. This in turn is determined by two important factors: circulating anti-mouse antibody titers; and timing of the rejection episode. Roughly 50 to 60 percent of patients who receive OKT3 will produce human anti-mouse antibodies (HAMA), generally in low titers (&lt;1:100). Low antibody titers do not affect the response to retreatment (reversal rate almost 100 percent) if the rejection episode occurs within 90 days after transplantation. On the other hand, titers above 1:100 or recurrent rejection beyond 90 days are associated with a reversal rate of less than 25 percent. The reversal rate is essentially zero when both high HAMA titers and late rejection are present. The utilization of other immunosuppressive agents, such as mycophenolate mofetil in combination with cyclosporine, may suppress the development of HAMA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a high-affinity, chimeric monoclonal antibody directed against CD20 antigen on B cells. It inhibits B-cell proliferation and induces cellular apoptosis. It is approved for treatment of refractory low-grade or follicular B-cell non-Hodgkin's lymphoma and rheumatoid arthritis.",
"   </p>",
"   <p>",
"    In transplantation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    has been used to reduce anti-donor ABO or HLA antibodies and to treat acute humoral rejection and to treat PTLD. Although the standard dosage is 375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    weekly for four doses, two studies reported successful treatment using a single, low dose rituximab (375 mg or 500 mg) for refractory antibody-mediated rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/18,33\">",
"     18,33",
"    </a>",
"    ]. The pharmacodynamics and studies for ABO-incompatible transplantation suggest that even lower doses of 100 to 200 mg may be effective in this setting and perhaps for treatment of antibody mediated rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (Anti-CD52 antibody, Campath-1H) is a humanized anti-CD52 monoclonal antibody that is approved for the treatment of chronic lymphocytic leukemia. CD52 antigen is present on T and B lymphocytes, natural killer cells, and, to a lesser extent, on",
"    <span class=\"nowrap\">",
"     monocytes/macrophages.",
"    </span>",
"    As reported in a few limited studies, it has also been used for the treatment of acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Alemtuzumab lyses lymphocytes via complement activation and via antibody-dependent cellular cytotoxicity.",
"   </p>",
"   <p>",
"    If proven efficacious, practical advantages with this agent would include peripheral, rather than central, venous access administration and a short treatment course. In the largest study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    reversed acute rejection in 25 of 40 (63 percent) of renal transplant recipients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    monotherapy with either steroid resistant rejection or &ge;Banff type 1B rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/38\">",
"     38",
"    </a>",
"    ]. Other adjunctive measures included reversal of tacrolimus weaning, steroid administration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . Infectious complications, however, were observed in 14 patients (35 percent). There were two patient deaths reported, one related to infection and the other to PTLD.",
"   </p>",
"   <p>",
"    While the reports using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    for treatment of acute rejection are limited in scope, continued investigation in the use of this agent for steroid-resistant rejection (with special interest for CD20+ B-cell steroid resistant rejection, cellular rejection &ge; Banff type 1B, or as an adjunct in the treatment of antibody mediated rejection) is warranted. The optimal dosing regimen is unclear, but the data from the use of alemtuzumab as an induction agent would suggest that one to two doses of 30 mg maximum should be administered. Given the significant and long-term depletion of lymphocytes present after the administration of alemtuzumab, care should be given to provide appropriate infectious prophylaxis, as with initial induction therapy. The maintenance immunosuppressive regimen following treatment of acute rejection may also need to be modified, as an intense regimen following alemtuzumab administration may predispose to an unacceptable risk of severe infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/41\">",
"     41",
"    </a>",
"    ]. As an example, the long-term follow-up of 15 renal transplant recipients who received alemtuzumab for treatment of acute rejection showed an excess of early infection-associated death when compared with a control group who received a steroid pulse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     IL-2 receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, the use of either IL-2 receptor blocker (anti-CD25 antibodies),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    or daclizumab, in the treatment of acute rejection approaches 10 percent. While these agents are indicated for induction in renal transplantation, there are no controlled studies reporting their use in the treatment of acute rejection. Given the lack of supportive data and the presumed absence of added benefit in treating acute rejection, other agents should preferentially be chosen for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESCUE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-antibody rescue therapy for refractory rejection is commonly based upon the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil to those not receiving these agents as part of their maintenance immunosuppressive regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled trials suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506) may be effective as rescue therapy for acute rejection that is unresponsive to treatment with corticosteroids and ATG therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. One report, for example, switched 77 patients with biopsy-proven ongoing acute rejection from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    to tacrolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/43\">",
"     43",
"    </a>",
"    ]. The overall response rate was 74 percent, with responders having a mean plasma creatinine concentration of 2.35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (207",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    at 14 months. Even dialysis-dependent patients had a 50 percent response rate. Similar results were found in another series of 73 patients, 100 percent of whom were resistant to steroids and 81 percent of whom were resistant to antilymphocyte antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/44\">",
"     44",
"    </a>",
"    ]. The graft survival rate was 75 percent at 12 months after tacrolimus administration.",
"   </p>",
"   <p>",
"    A subsequent trial demonstrated long-term graft survival following rescue therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/45\">",
"     45",
"    </a>",
"    ]. In this report, 125 of 169 patients (74 percent) had functioning renal grafts at a mean follow-up of 30 months.",
"   </p>",
"   <p>",
"    It is important to note that the speed of reversal of acute rejection with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is significantly slower than with either pulse corticosteroids or ATG. It may take several weeks for the maximal improvement in organ function to be observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach is the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil to allograft recipients with refractory rejection who are not being administered this agent as maintenance therapy. A number of studies have shown that such an approach is safe and effective. As an example, one randomized, open-label, multicenter study compared the efficacy and safety of mycophenolate mofetil administered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and maintenance corticosteroids for the treatment of refractory cellular rejection versus high-dose intravenous corticosteroids and conventional triple therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/46\">",
"     46",
"    </a>",
"    ]. Treatment with mycophenolate resulted in a 45 percent reduction in graft loss and death at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    as rescue therapy in refractory renal allograft rejection. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although intravenous immune globulin (IVIG) has been used in some centers for the treatment of antibody-mediated rejection (AMR), there is less experience with this agent in the treatment of cellular rejection that is refractory to steroids, OKT3 or ATG. A retrospective study of 17 such patients found that the administration of IVIG was associated with patient and graft survival rates of 94 and 71 percent, respectively, at a mean follow-up of 22 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/47\">",
"     47",
"    </a>",
"    ]; three of four with rejection resistant to ATG antibodies were rescued with IVIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Allograft irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized allograft irradiation has also been utilized for patients with allograft rejection in whom numerous courses of rescue immunotherapy have been administered or who have systemic infection. This modality was used in the earliest days of transplantation and was found to only have short-term efficacy.",
"   </p>",
"   <p>",
"    Anecdotally, such measures have occasionally successfully reversed rejection; however, there are limited data documenting its safety and efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Since the dose of radiation is low, it is not anticipated that radiation nephritis would develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=see_link\">",
"     \"Kidney disease following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy may be effective in treating antibody-mediated rejection (AMR) refractory to plasmapheresis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four kidney transplant recipients (two ABO-incompatible, one crossmatch positive, one with known risk factors) who were diagnosed with an AMR and failed standard therapy (average 11 days) with steroid, plasmapheresis, IVIG, thymoglobulin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      (three patients) or Campath (one patient) was treated with laparoscopic splenectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/50\">",
"       50",
"      </a>",
"      ]. Urine output improved immediately and serum creatinine decreased within 48 hours.",
"     </li>",
"     <li>",
"      Five patients who underwent a living donor renal transplant after desensitization for a positive crossmatch had an AMR [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/51\">",
"       51",
"      </a>",
"      ]. After rescue attempts with plasmapheresis and IVIG failed, they underwent splenectomy followed by plasmapheresis and IVIG. Allograft function returned in 48 hrs of the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ANTIBODY MEDIATED REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody-mediated rejection is often refractory to treatment modalities aimed at acute cellular rejection and, unless adequately treated, results in renal allograft loss in approximately 50 percent of cases. Acute AMR is an entity now better defined and often detected earlier in the clinical course based on the recognition of characteristic histologic findings, positive C4d staining, and the detection of donor specific antibodies (DSA). Prior descriptions often referred to AMR by various terms (most commonly vascular rejection). Antibody-mediated rejection was also often presumed to be the etiology when histology revealed severe vascular changes (Banff class III) or when the rejection episode was not responsive to the treatments described above (corticosteroids, ATG, OKT3) that primarily target T-cell rejection pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25946?source=see_link\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary data first suggested that patients with AMR might respond to treatment with plasmapheresis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, plasmapheresis plus intravenous immune globulin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunoadsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. Subsequently, other reports of successful outcomes using similar protocols have been reported. A detailed discussion of AMR and its treatment is presented elsewhere (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25946?source=see_link\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Plasma cell infiltrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, a renal allograft biopsy will demonstrate the presence of a significant plasma cell infiltrate. Although PTLD can be associated with this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/57\">",
"     57",
"    </a>",
"    ], a significant plasma cell infiltrate may also represent a form of antibody-mediated rejection, as positive C4d staining and the presence of donor specific antibodies and anti-endothelial antibodies may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with chronic antibody-mediated rejection associated with positive C4d staining, donor specific antibodies and often a histologic picture of chronic allograft glomerulopathy, the utility of using therapies targeting acute AMR in the setting of plasma cell rejection remains unclear. In general, allograft dysfunction in this setting may be resistant to treatment with steroids and antibody preparations, resulting in a poor graft survival of less than 50 percent at one year after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there appears to be rapid progression of allograft dysfunction in the setting of a significant plasma cell infiltrate, then treatment modalities targeting both cellular and antibody-mediated pathways can be considered, although there are no data to support this line of treatment. In the setting of significant plasma cell infiltrate with slow progression of allograft dysfunction, it is unclear if therapies used in the setting of AMR are of any benefit and augmentation of the maintenance immunosuppressive regimen may be the best approach.",
"   </p>",
"   <p>",
"    One report of eight patients with mixed antibody-mediated rejection and concomitant acute cell-mediated rejection had a good response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , a proteosomal inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/61\">",
"     61",
"    </a>",
"    ]. At present, the optimal treatment for this entity in the setting of either acute or chronic allograft dysfunction is unknown. The role of bortezomib requires further investigation.",
"   </p>",
"   <p>",
"    In our experience, focal plasma cell infiltrates associated with positive C4d staining, donor specific antibodies and an acute onset of graft dysfunction are reversible with treatment targeting antibody-mediated rejection. We would include IVIG in the treatment protocol. In contrast, a diffuse plasma cell infiltrate associated with negative C4d staining and a chronic worsening of graft function tends to be refractory to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114799311\">",
"    <span class=\"h1\">",
"     SUBCLINICAL AND BORDERLINE REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical rejection is defined as the presence of histologic evidence of acute rejection on biopsy without an elevation in the serum creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/62-69\">",
"     62-69",
"    </a>",
"    ]. It is unclear if the administration of therapy to patients with subclinical rejection improves clinical outcomes. Only a few studies have examined this question [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 72 patients who were being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and glucocorticoids, were randomly assigned to biopsy at 1, 2, 3, 6, and 12 months posttransplantation (biopsy group) or to biopsy at 6 and 12 months (control group) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/71\">",
"       71",
"      </a>",
"      ]. Subclinical rejection discovered at months 1, 2, and 3 in the biopsy group was treated with high-dose glucocorticoids. Compared with no treatment, corticosteroid therapy was associated with fewer episodes of acute rejection and with a lower serum creatinine concentration at two years (1.5 versus 2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [133 versus 183",
"      <span class=\"nowrap\">",
"       micromol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      However, in a later multi-center study, 240 renal transplant recipients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and glucocorticoids and randomly assigned to protocol biopsy arm or control arm with subclinical rejection treated with glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/70\">",
"       70",
"      </a>",
"      ]. At six months, there was no difference in renal function between groups. The authors concluded that protocol biopsy was not useful in the setting of stronger immunosuppression (ie,",
"      <span class=\"nowrap\">",
"       tacrolimus/mycophenolate/glucocorticoids)",
"      </span>",
"      and the resulting low prevalence of subclinical rejection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study with longer followup is required to determine whether surveillance biopsies combined with enhanced immunosuppression administered for the treatment of subclinical rejection improves long term outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also no consensus on the management of borderline rejection found on protocol biopsies, and in particular, whether anti-rejection treatment should be utilized. One study showed increased regulatory T cell activity in the peripheral blood of patients with borderline histologic changes and among those who have no evidence of rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/74\">",
"     74",
"    </a>",
"    ]. Another study suggested that patients with a higher ratio of FoxP3",
"    <sup>",
"     +",
"    </sup>",
"    regulatory T",
"    <sub>",
"    </sub>",
"    cells to CD3+ T cells on a six month protocol biopsy may have a better outcome than those with infiltrates with fewer regulatory T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/75\">",
"     75",
"    </a>",
"    ]. These findings raise a question on the utility of rejection treatment in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our current protocol is to treat a first episode of acute, predominantly cellular rejection with a steroid pulse. A biopsy should almost always precede the administration of any therapy, unless absolutely contraindicated. Because rejection can be mimicked by various infections such as BK virus-induced nephropathy, the administration of the steroid pulse should be delayed while awaiting results of the allograft biopsy and infectious evaluation, if these results can be promptly obtained.",
"   </p>",
"   <p>",
"    Our rationale for this strategy is that most transplant centers are experiencing acute rejection rates of 10 percent that are only slightly higher than BK nephropathy rates of 5 to 8 percent. In addition, the treatment of these conditions is diametrically opposed, and rarely rejection and BK nephropathy may be concurrent.",
"   </p>",
"   <p>",
"    Rapidly progressive allograft dysfunction as a result of BK nephropathy is unlikely. Thus, in the setting of severe acute renal failure with concern for significant graft injury without rapid intervention, it is acceptable to perform an urgent biopsy, pulse with one dose of steroids and await the initial biopsy results to guide further therapy. The possible coexistence of BK virus should still be evaluated in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When steroids are used, pulse intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , 3 to 7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, is given intravenously daily for three days, either alone or in combination with other immunosuppressive agents, such as ATG, depending upon the biopsy results",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the biopsy shows a Banff I cellular rejection, we use three days of pulse steroids and change to or augment the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil if necessary. We rapidly taper the steroids to the pre-rejection dose.",
"     </li>",
"     <li>",
"      If there is evidence of worsening graft function or a lack of a favorable clinical response without an adequate explanation after three days of pulse steroids, or if the initial biopsy revealed a Banff IB (with signs and symptoms of a more aggressive rejection [new uncontrolled hypertension, rising serum creatinine]) or Banff II-III cellular rejection, we administer pulse steroids in conjunction with thymoglobulin at a dose of either 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for three days or 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for five days (total dose 7.5 to 9",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      This approximates the average dose of thymoglobulin of 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      that led to the FDA approval of thymoglobulin for treatment of steroid resistant acute rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?4/52/4938/abstract/21\">",
"       21",
"      </a>",
"      ]. We would change to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil if the patient was not already on this combination prior to transplantation or augment the dose of either agent if necessary. Steroids are rapidly tapered to pre-rejection levels, once a response is achieved.",
"      <br/>",
"      <br/>",
"      If there is not an acceptable response to this regimen, particularly if C4d staining is negative, we will rebiopsy to make sure that AMR is not present. This includes repeat C4d staining and an analysis for donor specific antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25946?source=see_link\">",
"       \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If there is no evidence of AMR on repeat biopsy and there is continued evidence of refractory cellular mediated rejection, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      or IVIG may be considered. In our experience, isolated cellular mediated rejection that is refractory to treatment with corticosteroids with or without thymoglobulin is rare.",
"      <br/>",
"      <br/>",
"      It is important to confirm the diagnosis and degree of rejection by renal biopsy before initiating prolonged courses of high dose steroids or adding agents such as ATG or alemtuzumab. In some cases, the steroid pulse has reversed the rejection process, but renal failure persists due to acute tubular necrosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      toxicity, both of which can accompany acute rejection.",
"     </li>",
"     <li>",
"      If the biopsy suggests an element of AMR either alone or in combination with cellular rejection, we treat aggressively to remove or inhibit circulating anti-donor antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25946?source=see_link\">",
"       \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cessation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision when to stop treating patients with recurrent rejection is difficult but important and is determined by the overall clinical status of the patient. We recommend stopping therapy if:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A concurrent infectious process represents undue risk with further intensification of immunosuppression.",
"     </li>",
"     <li>",
"      There is no evidence of response following an intense courses of treatment with agents such ATG or OKT3 and there is no evidence of AMR on repeat biopsy (which would dictate an alternate treatment regimen) or any other apparent extenuating etiology for continued renal failure.",
"     </li>",
"     <li>",
"      Repeat renal biopsy shows nonviable kidney tissue. We have found it useful to obtain a trichrome stain to assess fibrosis to help in this decision. The extent of chronic changes on the initial biopsy can also help guide the intensity and duration of immunosuppression. If there is little evidence for a reversible process, the risk of infection and malignancy resulting from high dose immunosuppression probably outweighs any benefit.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/1\">",
"      Cohen DJ, St Martin L, Christensen LL, et al. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 2006; 6:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/2\">",
"      Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/3\">",
"      Khwaja K, Asolati M, Harmon J, et al. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 2004; 4:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/4\">",
"      Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. Am J Transplant 2005; 5:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/5\">",
"      Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443--a phase I clinical trial and pilot rescue study. Transplantation 1992; 53:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/6\">",
"      Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/7\">",
"      Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003; 3:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/8\">",
"      Webster AC, Pankhurst T, Rinaldi F, et al. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation 2006; 81:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/9\">",
"      Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/10\">",
"      Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/11\">",
"      Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033.",
"     </a>",
"    </li>",
"    <li>",
"     www.ustransplant.org/annual_reports/2008, accessed 2/10.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/13\">",
"      Gray D, Shepherd H, Daar A, et al. Oral versus intravenous high-dose steroid treatment of renal allograft rejection. The big shot or not? Lancet 1978; 1:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/14\">",
"      Vineyard GC, Fadem SZ, Dmochowski J, et al. Evaluation of corticosteroid therapy for acute renal allograft rejection. Surg Gynecol Obstet 1974; 138:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/15\">",
"      Shinn C, Malhotra D, Chan L, et al. Time course of response to pulse methylprednisolone therapy in renal transplant recipients with acute allograft rejection. Am J Kidney Dis 1999; 34:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/16\">",
"      Briggs D, Dudley C, Pattison J, et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. Transplantation 2003; 75:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/17\">",
"      Pichette, V, Bonnardeaux, A, Prudhomme, L, et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kid Dis 1996; 28:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/18\">",
"      Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/19\">",
"      Zhang PL, Malek SK, Prichard JW, et al. Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without Campath-1H (alemtuzumab) induction therapy. Am J Transplant 2005; 5:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/20\">",
"      Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/21\">",
"      Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/22\">",
"      Pham PT, Pham PM, Miller JM, Pham PC. Polyclonal antibody-induced serum sickness presenting as rapidly progressive descending paralysis. Transplantation 2007; 83:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/23\">",
"      Leunissen, KM, Kootstra, G, Mooy, JM, et al. Plasmapheresis and RATG-induced serum sickness. Clin Transplant 1988; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/24\">",
"      Christiaans MH, van Hooff JP. Plasmapheresis and RATG-induced serum sickness. Transplantation 2006; 81:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/25\">",
"      Tanriover B, Chuang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation 2005; 80:279.",
"     </a>",
"    </li>",
"    <li>",
"     Boothpur et al, Am J Kidney Dis 55:141-143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/27\">",
"      Schroeder TJ, First MR. Monoclonal antibodies in organ transplantation. Am J Kidney Dis 1994; 23:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/28\">",
"      A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 1985; 313:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/29\">",
"      Norman DJ, Barry JM, Bennett WM, et al. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Am J Kidney Dis 1988; 11:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/30\">",
"      Hricik DE, Zarconi J, Schulak JA. Influence of low-dose cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection. Transplantation 1989; 47:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/31\">",
"      Norman, DJ, Shield, CF, Henell, KR, et al. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 1988; 46:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/32\">",
"      Broeders N, Wissing KM, Crusiaux A, et al. Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients. J Am Soc Nephrol 1998; 9:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/33\">",
"      Mulley WR, Hudson FJ, Tait BD, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009; 87:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/34\">",
"      Genberg H, Hansson A, Wernerson A, et al. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/35\">",
"      Toki D, Ishida H, Horita S, et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/36\">",
"      Shirakawa H, Ishida H, Shimizu T, et al. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant 2011; 25:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/37\">",
"      Friend PJ, Rebello P, Oliveira D, et al. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. Transplant Proc 1995; 27:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/38\">",
"      Basu A, Ramkumar M, Tan HP, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 2005; 37:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/39\">",
"      Csapo Z, Benavides-Viveros C, Podder H, et al. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant Proc 2005; 37:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/40\">",
"      Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Campath and renal transplant rejection. Clin Transplant 2004; 18:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/41\">",
"      Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/42\">",
"      Clatworthy MR, Friend PJ, Calne RY, et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 2009; 87:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/43\">",
"      Jordan ML, Shapiro R, Vivas CA, et al. FK506 \"rescue\" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/44\">",
"      Woodle ES, Thistlethwaite JR, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 1996; 62:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/45\">",
"      Jordan ML, Naraghi R, Shapiro R, et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation 1997; 63:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/46\">",
"      Rescue therapy with mycophenolate mofetil. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Clin Transplant 1996; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/47\">",
"      Luke, PW, Scantlebury, VP, Jordan, ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin in renal transplant recipients. Transplantation 2001; 71:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/48\">",
"      Chen LM, Godinez J, Thisted RA, et al. New scoring system identifies kidney outcome with radiation therapy in acute renal allograft rejection. Int J Radiat Oncol Biol Phys 2000; 46:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/49\">",
"      Wahl AO, Small W Jr, Dixler I, et al. Radiotherapy for rejection of renal transplant allografts refractory to medical immunosuppression. Am J Clin Oncol 2006; 29:551.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan, B, Gangemi, A, Thielke, J, et al. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007, 83:28.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/51\">",
"      Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/52\">",
"      Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/53\">",
"      Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/54\">",
"      B&ouml;hmig GA, Regele H, Exner M, et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/55\">",
"      Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/56\">",
"      Lennertz A, Fertmann J, Thomae R, et al. Plasmapheresis in C4d-positive acute humoral rejection following kidney transplantation: a review of 4 cases. Ther Apher Dial 2003; 7:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/57\">",
"      Charney DA, Nadasdy T, Lo AW, Racusen LC. Plasma cell-rich acute renal allograft rejection. Transplantation 1999; 68:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/58\">",
"      Desvaux D, Le Gouvello S, Pastural M, et al. Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high gamma-interferon expression and poor clinical outcome. Nephrol Dial Transplant 2004; 19:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/59\">",
"      Meehan SM, Domer P, Josephson M, et al. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. Hum Pathol 2001; 32:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/60\">",
"      Aiello FB, Calabrese F, Rigotti P, et al. Acute rejection and graft survival in renal transplanted patients with viral diseases. Mod Pathol 2004; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/61\">",
"      Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/62\">",
"      Rush DN, Henry SF, Jeffery JR, et al. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994; 57:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/63\">",
"      Shapiro R, Jordan ML, Scantlebury VP, et al. Renal allograft rejection with normal renal function in simultaneous kidney/pancreas recipients: does dissynchronous rejection really exist? Transplantation 2000; 69:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/64\">",
"      Roberts IS, Reddy S, Russell C, et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation 2004; 77:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/65\">",
"      Kee TY, Chapman JR, O'Connell PJ, et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation 2006; 82:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/66\">",
"      Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/67\">",
"      Scholten EM, Rowshani AT, Cremers S, et al. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006; 17:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/68\">",
"      Ser&oacute;n D, Moreso F. Protocol biopsies in renal transplantation: prognostic value of structural monitoring. Kidney Int 2007; 72:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/69\">",
"      Thaunat O, Legendre C, Morelon E, et al. To biopsy or not to biopsy? Should we screen the histology of stable renal grafts? Transplantation 2007; 84:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/70\">",
"      Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007; 7:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/71\">",
"      Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/72\">",
"      Kurtkoti J, Sakhuja V, Sud K, et al. The utility of 1- and 3-month protocol biopsies on renal allograft function: a randomized controlled study. Am J Transplant 2008; 8:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/73\">",
"      Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 Suppl 15:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/74\">",
"      N&eacute;meth D, Ovens J, Opelz G, et al. Does borderline kidney allograft rejection always require treatment? Transplantation 2010; 90:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/52/4938/abstract/75\">",
"      Bestard O, Cruzado JM, Rama I, et al. Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008; 19:2020.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7358 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-743D36F484-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4938=[""].join("\n");
var outline_f4_52_4938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INADEQUATE IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Banff classification of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10975968\">",
"      - 1. Normal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10975982\">",
"      - 2. Antibody-mediated changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10976039\">",
"      - 3. Borderline changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10976054\">",
"      - 4. T--cell mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10976076\">",
"      - 5. Interstitial fibrosis and tubular atrophy, without evidence of any specific etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10976083\">",
"      - 6. Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10976098\">",
"      Major modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PULSE CORTICOSTEROIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POLYCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antithymocyte globulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MONOCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OKT-3 (Anti-CD3 antibody)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Role in recurrent rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IL-2 receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ADDITIONAL RESCUE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Allograft irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ANTIBODY MEDIATED REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Plasma cell infiltrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114799311\">",
"      SUBCLINICAL AND BORDERLINE REJECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cessation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25946?source=related_link\">",
"      C4d staining in renal allografts and treatment of antibody mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6266?source=related_link\">",
"      Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/62/38880?source=related_link\">",
"      Cyclosporine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40084?source=related_link\">",
"      Differential diagnosis of infection following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36517?source=related_link\">",
"      Psychiatric aspects of organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27190?source=related_link\">",
"      Sirolimus: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=related_link\">",
"      Tacrolimus: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_52_4939="Difficult airway children";
var content_f4_52_4939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical assessment to identify signs of a difficult airway in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Difficulty",
"       </td>",
"       <td class=\"subtitle1\">",
"        Signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positioning",
"       </td>",
"       <td>",
"        Prominent or misshapen occiput, short neck, poor neck mobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bag-mask ventilation",
"       </td>",
"       <td>",
"        Facial anomalies, facial trauma (including burns)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngoscopy",
"       </td>",
"       <td>",
"        Small mouth, small mandible, abnormal palate, large tongue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intubation",
"       </td>",
"       <td>",
"        Signs of upper airway obstruction (hoarseness, stridor, drooling, upright position of comfort)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4939=[""].join("\n");
var outline_f4_52_4939=null;
var title_f4_52_4940="Intraosseous cannula placement site by patient age";
var content_f4_52_4940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intraosseous cannula placement site by patient age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patient age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intraosseous site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Infant (under 1 year)",
"       </td>",
"       <td>",
"        Proximal tibia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal femur",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Child (1-12 years)",
"       </td>",
"       <td>",
"        Proximal tibia*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal tibia or fibula",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Skeletally immature adolescent",
"        <sup>",
"         &bull;",
"        </sup>",
"        (12-18 years)",
"       </td>",
"       <td>",
"        Proximal tibia*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal tibia or fibula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sternum",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Over 18 years",
"       </td>",
"       <td>",
"        Proximal tibia*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proximal humerus",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal tibia or fibula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sternum",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Battery-powered or impact-driven devices are typically required to place an intraosseous cannula through the bony cortex of the proximal tibia in patients older than six years of age.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Age at full skeletal maturity varies according to gender and individual patient characteristics.",
"      <br>",
"       &Delta; Sternal intraosseous cannula placement should only be attempted using devices specifically designed for that placement site.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        The proximal humerus site should only be used in skeletally mature patients.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4940=[""].join("\n");
var outline_f4_52_4940=null;
var title_f4_52_4941="Rx of Pasteurella multocida";
var content_f4_52_4941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic susceptibility of Pasteurella multocida",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Highly susceptible",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Penicillin G",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Penicillin V",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ampicillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amoxicillin-clavulanate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Piperacillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Piperacillin-tazobactam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefoxitin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefuroxime",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefpodoxime",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefotaxime",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetracycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimethoprim-sulfamethoxazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ciprofloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Levofloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Minocycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Doxycycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ceftriaxone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Moxifloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tigecycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ertapenem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Imipenem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meropenem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Doripenem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aztreonam",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Moderately susceptible",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gentamicin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tobramycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amikacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nafcillin*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cephalothin&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefazolin&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Azithromycin",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Usually resistant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vancomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clindamycin",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Susceptible by Kirby-Bauer disc but MIC higher than other penicillins.",
"     <br>",
"      &bull; Susceptible by Kirby-Bauer disc but MIC higher than second- and third-generation cephalosporins.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Weber, DJ, Hanson, AR. Infections resulting from animal bites. Infect Dis Clin North Am 1991; 5:663.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4941=[""].join("\n");
var outline_f4_52_4941=null;
var title_f4_52_4942="17 alpha hydroxylase deficiency";
var content_f4_52_4942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Synthetic defect in CYP17 (17-alpha-hydroxylase) deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathways of adrenal steroid synthesis. A synthetic defect in 17-alpha-hydroxylase leads to diminished cortisol synthesis, increased release of ACTH, accumulation of the mineralocorticoid deoxycorticosterone (leading to hypertension and hypokalemia) and diminished adrenal androgen and estrogen production (leading to hypogonadism in females and pseudohermaphroditism in males).",
"    <div class=\"footnotes\">",
"     The numbers at the arrows refer to specific enzymes: 17&alpha;: 17&alpha;-hydroxylase (P450c17); 17,20: 17,20 lyase which is part of the P450c17 enzyme; 3&beta;: 3&beta;-hydroxysteroid dehydrogenase; 21: 21-hydroxylase (P450c21); 11&beta;: 11&beta;-hydroxylase; (P450c11); 18 refers to the two-step process of aldosterone synthase (P450c11as), resulting in the addition of an hydroxyl group that is then oxidized to an aldehyde group at the 18-carbon position; ?: unclear if pathway functions in vivo; DHEA: dehydroepiandrostenedione; 17KSR: 17-ketosteroid reductase; and A: aromatase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4942=[""].join("\n");
var outline_f4_52_4942=null;
var title_f4_52_4943="Ileocolic anastomosis - Transverse enterostomies";
var content_f4_52_4943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ileocolic anastomosis - Transverse enterostomies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_52_4943=[""].join("\n");
var outline_f4_52_4943=null;
